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MYCN-amplification is a high-risk factor in neuroblastoma which contributes to a poor 
prognostic outcome. Here data is presented showing that both short-interfering (si) 
RNA depletion and treatment by small molecule inhibitors (SMI) of lysine-specific 
histone methyltransferase Euchromatic Histone Lysine Methyltransferase 2 (G9a) 
leads to impaired growth in all tested neuroblastoma cell lines. Furthermore, in cell 
lines representative of high-risk neuroblastomas with MYCN-amplification, there is a 
significant increase in apoptosis and cell death. There is also a significant reduction in 
MYCN protein in MYCN-overexpressing cells, including in SHEP-21N cell line with 
inducible MYCN expression, after both G9a knockdown and SMI treatment 
independently. This suggests there is a synthetic lethal relationship between G9a and 
MYCN.  
G9a-associated reduction of MYCN leads to the re-expression of repressed tumour 
suppressor and pro-apoptotic factor BCL-2 Related Ovarian Killer (BOK). Quantitative 
gene expression analysis and immunoblotting of neuroblastoma cell lines shows an 
increase in BOK after both G9a depletion and SMI treatment independently which is 
only apparent in the MYCN-overexpressing cell lines; this increase in BOK leads to 
apoptosis, and BOK depletion was able to rescue G9a inhibition-associated apoptosis.  
Together, these studies show that G9a is a major oncoprotein in neuroblastoma 
tumourigenesis and a novel regulator of MYCN protein; this suggests that together 
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1.1 The Hallmarks of Cancer 
Cancer is a multistep disease that was originally thought to comprise of six biological 
capabilities during development of human tumours; this has now grown to ten which 
are illustrated in Figure 1.1, along with potential therapeutics to target them. These 
include sustaining proliferative signalling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis (1). Causal to these capabilities is genomic instability which enables 
the genetic diversity necessary to generate these hallmarks. Somatic evolution is the 
acquisition and build-up mutations and epimutations in somatic cells (2). This clonal 
selection and expansion based on which genetic attributes help the tumour to survive 
and help to drive these hallmarks.  
 
Figure 1.1– Hallmarks of cancer with targeted therapeutic treatments taken from 




1.1.1 Oncogenes, mutations, and gene amplification 
A proto-oncogene is a gene that has the potential to become oncogenic and cause 
cancer by becoming mutated and/or expressed at elevated levels relative to normal. 
Oncogenes encode proteins involved in cell proliferation and/or apoptosis. These 
include transcription factors, chromatin remodelers, growth factors and growth factor 
receptors, signal transducers, and apoptosis regulators (3).  Many types of mutations 
can occur in oncogenes to change the structure to create an enhanced oncoprotein. 
For example, mutations in RAS gene codons 12, 13, or 61 encode for a constitutively 
active version of the triphosphatases that links tyrosine kinases to downstream serine 
and threonine kinases to induce continuous cell growth (3).  
The number of mutations found in any cancer can vary from 10 or 20 to thousands. 
Only a few of these mutations are driver mutations that are subject to selection during 
tumourigenesis, for example MYC and ABL1 (4). The vast majority of gene mutations 
are just passengers which don’t actively contribute to tumourigenesis and are 
therefore not under a selection pressure (2).  
Another oncogenic mechanism is gene amplification is an increase in copy number of 
a particular region of a chromosome arm. This leads to the overexpression of the 
amplified genes and thus these become oncogenic. An example is the amplification 
ERBB1 and ERBB2 in glioblastoma and breast cancer respectively (5).  
1.1.2 Tumour Suppressors 
A tumour suppressor gene is defined as a gene that normally inhibits cell division and 
protects the cell from becoming oncogenic. There are many examples of known 
tumour suppressor genes such as TP53 (6), APC (7), and PTEN (8).  
Tumour suppressors act through many biological functions to facilitate protection from 
tumourigenesis (9). For example, tumour suppressors can act at various stages of cell 
division to facilitate a smooth transition through the cell cycle. Tumour suppressor RB 
can act to repress genes necessary for the cell cycle to continue thus halting cell 
division in G1 phase. If DNA damage is recognised, cell division will also be brought 
to a halt. ATM kinase for example, recognises double-strand DNA breaks and so 
phosphorylates substrates to initiate cell cycle checkpoint responses and DNA repair 
processes (10). If this DNA damage cannot be fixed, p53 can then induce apoptosis 
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to remove the faulty cell. A mutation in a tumour suppressor at any of these steps 
could potentially lead to tumourigenesis.  
Unlike oncogenes, tumour suppressor genes necessitate a mutation in both alleles of 
the gene to render the tumour inhibitory power of the encoded protein obsolete. If only 
one of these alleles is damaged, the second can still generate the correct protein; this 
is Knudson’s two-hit hypothesis in which tumour suppressor retinoblastoma protein 
(pRb) was first documented (11). There are exceptions to this rule however, as 
mutations in one allele of  TP53 can cause a dominant negative effect by inactivating 
the wild type function of p53. This effect was shown in transgenic mouse models 
expressing p53 mutated at residue 135 in a p53+/− background. These had a higher 
incidence of tumourigenesis relative to p53+/− mice without the transgene (12), 
suggesting this mutant can induce carcinogenesis in the presence of the wild type p53. 
This has also been observed in human cancers, as dominant negative mutations of 
p53 are associated with the early onset of glioblastoma (13). The mechanism for this 
negative dominant effect suggests that missense mutants of p53 prevent wild type p53 
from binding to p53 target gene promoters, such as p21 and MDM2, which prevents it 
from carrying out its tumour suppressor function (14). 
There are also a group of genes and proteins which prevent tumour cells from 
metastasising which are known as metastasis repressors. The first metastasis-
suppressor gene, NME1 (nm23), is active in melanoma, breast, and colon cancers 
and works to inhibit kinases that promote cell division (15). The proteins can be used 
as prognostic markers, for example, high expression of kinase NME1 is correlated with 




1.1.3 Apoptosis pathways 
There are two main pathways that lead to caspase-dependent apoptosis (20-22), 
outlined in Figure 1.2. These are the extrinsic (or death-receptor) and intrinsic (or 
mitochondrial) pathways. The extrinsic pathway involves stimulation of death 
receptors by death ligands, for example Fas ligand binds to Fas receptors to trigger 
downstream apoptosis by activating a caspase cascade (23). The intrinsic pathway is 
characterised by mitochondrial outer membrane permeabilisation (MOMP) following 
intrinsic stimuli such as DNA damage (24) and the consequent release of cytochrome 
c into the cytosol through a pore in the membrane. Cytochrome c then binds with 
apoptosis initiator protein APAF1 to form the apoptosome which activates caspase-9 
(25).  
There is also evidence to suggest the two pathways are linked as both pathways 
activate initiator caspases which activate the executioner caspases. Cleavage of BID 
by caspase-8 leads to the generation of cleaved BID that is translocated to the 
mitochondria to drive the intrinsic pathway (26). This shows that there is some 
crosstalk between the intrinsic and extrinsic pathways to strengthen the apoptotic 
signal (21). 
1.1.4 Pro- and anti-apoptotic factors 
The BCL-2 family of proteins regulate cell death at the mitochondrial level. These can 
be split it to two antagonistic groups: pro-apoptotic and anti-apoptotic. The balance 
between pro- and anti-apoptotic proteins determines the sensitivity of the cells towards 
apoptotic stimuli; excess of pro-apoptotic factors makes the cells sensitive to apoptotic 
stimuli, whereas excess of anti-apoptotic factors decreases their sensitivity. Table 1.1 
shows the members of each family. All anti-apoptotic proteins are multi-region proteins 
containing four BCL-2 homology (BH) regions, BH1-BH4. Pro-apoptotic factors are 
subdivided further; BAK and BAX oligomerise to perform MOMP, whereas BID, 
BIM/BAD, and NOXA promote apoptosis through activation of BAX or BAK or inhibition 
of anti-apoptotic factors (27). The structure of the BCL-2 family is defined by the 
presence of BH domains- short stretch of conserved sequence around 20 amino acid 
residues in length (28, 29). This is represented in Figure 1.3. For the purposes of this 




Figure 1.2 – a basic graphical representation of death-receptor (extrinsic) and 
mitochondrial (intrinsic) apoptotic pathways adapted from Igney et al (21).  
Extrinsic pathway – Action of death ligand binding to complementary death-ligand receptor 
initiates downstream apoptosis. Intrinsic pathway – Apoptotic stimulus, such as DNA 






Table 1.1– Classification of BCL-2 family proteins adapted from Siddiqui et al  (27). 
Two groups of the BCL-2 family are either anti-apoptotic or pro-apoptotic. Anti-apoptotic 
proteins are multi-region proteins which contain four BH domains. Multi-region BAK, BAX, 
BOK, and BID have more than one BH domain structurally similar to the parent protein BCL-
2. BIM, BAD, and NOXA contain only the BH3 region. All contain a C-terminal transmembrane 
domain, a membrane-bound region (MBR), that enables translocation or localisation to the 





Figure 1.3 – Basic structural representation of the three branches of the BCL-2 family.  
The BH domains are numbered, with BH3 common to all branches (yellow). MBR represents 
the membrane-bound region that enables translocation or localisation to the MOM or ER. 
  
Family BCL-2 
Group Pro-apoptotic Pro-survival 





















1.1.5 Normal regulation of multi-region apoptotic factors 
There are distinct mechanisms by which these apoptotic factors are regulated. For 
example, following an intrinsic death stimulus, pro-apoptotic BAX and BAK homo-
dimerise and translocate to the outer mitochondrial membrane (OMM) from the cytosol 
where they undergo a conformational change to form the structures necessary for 
MOMP (30-32). This homo-dimerisation is dominant irrespective of the presence of 
survival factors (33). Furthermore, pro-apoptotic BAK, which is normally found 
localised to the OMM, can form complexes with anti-apoptotic MCL-1 which negatively 
regulates the BAK’s pro-apoptotic activity (34). This regulation is outlined in Figure 
1.4. 
Pro-apoptotic factor BOK is a relatively recent addition having been cloned in a yeast 
two-hybrid screen of ovarian cDNA (35). BOK hetero-dimerises with anti-apoptotic 
BCL-2-member MCL-1 which in turn regulates apoptosis. It has previously been 
suggested to play a role in ER-stress induced cell death (36, 37), and more recently a 
role in the mitochondrial apoptotic pathway (38). In addition, other transcriptional 
regulators of BOK expression include members of the E2F family of transcription 
factors as both E2F1 and E2F3 can associate with the BOK promoter in vivo to 
promote transcription (39). 
1.1.6 Regulation of apoptosis in cancer 
A major hallmark of cancer is evading apoptotic cell death which is normally triggered 
in response to physiologic stresses that cancer cells experience during the course of 
tumorigenesis. This plays a critical role in the initiation and progression of cancers. 
Tumours have been shown to use multiple mechanisms to regulate apoptosis by 
upregulating expression of anti-apoptotic oncogenes or downregulating pro-apoptotic 
tumour suppressor genes. For example, increased expression of anti-apoptotic BCL-
2 in follicular lymphoma helps the tumour survive which suggests it and other anti-





Figure 1.4 – Mediation of the mitochondrial apoptotic pathway by the BCL-2 family of 
proteins taken from Moldoveanu et al (41). 
When cellular stress activates more pro-apoptotic BH3-only proteins to override the anti-
apoptotic response, BAK and BAX are stimulated to form pores in the outer mitochondrial 
membrane (OMM). This releases cytochrome c (Cyt c) into the cytosol to activate the 
apoptosome and downstream apoptosis.  
 
1.2 Epigenetics and cancer 
1.2.1 The epigenetic machinery of normal cells 
In addition to the genetic loss of tumour suppressor gene function, they can be 
functionally eliminated as a result of epigenetic silencing. DNA methylation, and 
covalent histone modifications are epigenetic mechanisms. These alter the structural 
dynamics of chromatin to regulate the functioning of the genome and so can silence 
tumour suppressor genes. 
1.2.1.1 DNA methylation 
DNA methylation occurs by modifying the cytosine residues in CpG dinucleotide rich 
stretches (CpG islands) in promoter regions of a gene (42). DNA methylation leads to 
gene silencing by both preventing and promoting the recruitment of regulatory proteins 
to DNA, for instance, blocking transcription factor c-MYC from accessing binding sites 
to repress gene expression (43). DNA methylation patterns are governed by the 
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cooperative activity of de novo methyltransferases DNMT3A and DNMT3B, and 
maintenance methyltransferase DNMT1. De novo adds methyl groups to 
unmethylated cytosines, whereas maintenance adds methyl groups to DNA that has 
one strand already methylated; de novo methyltransferases set the methylation 
patterns, which are maintained by the maintenance methyltransferase. Non-covalent 
mechanisms consist of nucleosome remodelling and the replacement of canonical 
histones with specialised variants. These are important in how the structure of the 
chromatin regulates gene activity. Nucleosome mapping has shown the precise 
positioning of nucleosomes with nucleosome free regions (NFRs) present at 5’ and 3’ 
ends of genes thought to provide assembly and disassembly sites of the transcription 
apparatus (44). The presence or absence of  nucleosomes in NFRs are correlated 
with active and repressed gene transcription respectively (45, 46). When histone 
variants H3.3 and H2A.Z are incorporated into nucleosomes, they can influence 
nucleosome occupancy and therefore gene activity (47). These are preferentially 
enriched at promoters of either active genes or genes poised for activation (48).  
1.2.1.2 Covalent histone modifications  
Chromatin is made of multiple nucleosome components which contain ~146 base 
pairs of DNA wrapped around an octamer of four core histone proteins (H2A and B, 
H3, and H4) (49). H1 is adjacent to the nucleosome and functions to keep the DNA in 
place that is wrapped around the nucleosome. 
Histones contain a protruding lysine rich N- terminal tail that are subject to reversible 
covalent modifications (Figure 1.5). These include lysine (K) and arginine (R) 
methylation, acetylation, ubiquitylation, and phosphorylation. There are over 60 
different histone residues where modifications have been detected (50). These 
modifications change the chromatin state by modifying the affinity of the histone for its 
negatively charged back bone, thus opening and closing genes off to transcription 
factors and RNA polymerases, thereby repressing or activating target genes. This also 
suggests that there is a vast amount of potential functional responses as a result. The 
multitude of modifications also implies that there is a degree of crosstalk and regulation 
between the modifications and their relative function. Histone writers, erasers, and 
readers add, remove, and recognise these post-translational modifications 
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respectively. Writers are divided in to groups based on the specific residue they add 
or remove, whereas readers direct a specific translational response as a result.  
1.2.1.2.1 Histone acetylation and ubiquitylation 
The addition of acetyl groups to lysine residues on the histone tail changes the positive 
charge of histone tails to promote the opening of DNA to become more accessible to 
transcription factors (51, 52). Histone acetylation is mediated by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) which add and remove 
acetyl groups respectively. 
Ubiquitylation of lysine residues on histone tails does not lead to proteasomal 
degradation as would happen normally, instead acting as a signalling molecule whose 
addition (ubiquitylation) and removal (deubiquitylation) denotes transcriptional 
activation (53). 
1.2.1.2.2 Lysine methylation 
Lysine residues on histone 3 and histone 4 can be methylated. This occurs by 
transferring one, two, or three molecules from S-adenosyl-L-methionine (SAM) to the 
ɛ-amino group of the target lysine residue (54). These methylation patterns are 
associated with both transcriptional activation or repression (55). For example, 
methylation of histone H3K4, H3K36, or H3K79 is associated with transcriptional 
activation (56), whereas methylation of H3K9 and H3K27 are associated with 
transcriptional repression. Furthermore, within this, the degree of methylation can also 
determine the activity of the gene. For example, tri-methylated H3K4 and mono-
methylated H3K9 typifies active genes (57, 58) yet di- and tri-methylated H3K9 are 






Figure 1.5 – Post-translational modifications sites on histone tails 
DNA is wrapped around the core histone octamer, a nucleosome. This consists of  H2A and 
B, H3, and H4. These histones protrude tails which are modified at specific residues, lysine 







Table 1.2 – Histone lysine methylation modifications in gene regulation 
Lysine methylation marks can act as transcriptionally active (A) or repressive (R) marks.  
 
The location of the methylated-lysine residue along with the degree of methylation are 
also associated with altering gene expression. For example, tri-methylation is 
associated with gene repression on H3K27 (60), however H3K4me3 is associated with 
active transcription (63, 65). This suggest that the effects of methylation are context-
dependent. 
Furthermore, there are also instances of the same modifications being associated with 
opposing activities, such as H3K4me2 and me3 which can both be associated with 
transcriptional activation and repression (66). This activity change is probably due to 
different chromatin effector proteins recognising the methylation marks. Table 1.3 
shows all the lysine HMTs and demethylases, and their respective modifications. 
1.2.1.2.3 Arginine methylation 
Arginine methylation is a common PTM that is carried out by arginine 
methyltransferase (PRMT) family (67).  These catalyse the transfer of methyl groups 
from S-adenosylmethionine (SAM) to arginine residues. There are three main forms 
of methylarginines identified in eukaryotes: mono-methylarginine (MMA), asymmetric 
dimethylarginine (aDMA), and symmetric dimethylarginine (sDMA). PRMTs cover 
three categories dependent on their catalytic activity; type I (PRMT1, PRMT2, PRMT3, 
PRMT4, PRMT6, and PRMT8) and II (PRMT5 and PRMT9) perform MMA before the 
establishment of aDMA or sDMA respectively (68). PRMT7 is a type III enzyme that 
only catalyses formation of MMA; only known substrate is histones thus far (69).  
Arginine methylation plays a crucial role in gene regulation as the methylation marks 
PRMTs  deposit on histones act as activating (H4R3me2a, H3R2me2s, H3R17me2a, 
H3R26me2a) or repressive (H3R2me2a, H3R8me2a, H3R8me2s, H4R3me2s) marks. 
Type of histone 
modification 
Histone and residue 






A (60) A (60) A (60, 61)  A (60) A (60) 




R (60) R (60) 
A (61), R 
(60) 
A (64)  R (62) 
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There are also non-histone targets of PRMTs, for example PRMT1 directly methylates 
Ash2L to positively regulate its transcription (70). 
 
 
Table 1.3 – Histone 3 and 4 lysine residue methyl group modifying enzymes 
Histone lysine methylation writers and erasers. The residue and the type of methyl 
modification are shown along with the reference it is shown in. 
1.2.1.2.4 Protein Demethylation 
Protein demethylases were first documented in 2004 when LSD1/KDM1 was identified 
as part of a multiprotein corepressor complex that contains histone deacetylase-1 and-
2 and demethylase activities (90, 96). Prior to this, deposited methylation marks where 
Lysine Methyltransferase Residue Methylated Mono- Di- Tri- 
SUV39H1/ KMT1A H3K9   (71, 72) 
SUV39H2/ KMT1B H3K9   (72) 
EHMT2/G9a/ KMT1C H3K9 (72, 73) (72, 73) (74, 75) 
EHMT1/GLP/ KMT1D H3K9 (72, 73) (72, 73) (74, 75) 
SETDB1/ KMT1E H3K9 (76, 77) (77) (77) 
SETD1A/ KMT2F H3K4 (78) (78) (78) 
SETD1B/ KMT2G H3K4   (79) 
SET2/ KMT3A H3K36 (80) (80) (80) 
NSD2/KMT3F H3K36 (81) (81)  
DOT1L/ KMT4 H3K79 (82, 83) (82, 83) (82, 83) 
PR-Set7/ KMT5A H4K20 (84)   
SUV420H1/ KMT5B H4K20  (85, 86) (85, 86) 
SUV420H2/ KMT5C H4K20  (85, 86) (85, 86) 
EZH2/ KTM6A H3K27  (87) (87) 
EZH1/ KMT6B H3K27 (88) (87) (87) 




Mono- Di- Tri- 
LSD1/KDM1A H3K4/ H3K9 (90, 91) (90, 91)  
KDM2A H3K36  (92)  





KDM3A H3K9 (94) (94)  
KDM4A H3K9, H3K36   (95) 
KDM4B H3K9   (95) 
KDM4C H3K9, H3K36   (95) 
KDM4D H3K9  (95) (95) 
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thought to be irreversible. Lysine demethylation is catalysed by two families of lysine 
demethylases- the flavin-dependent KDM1 enzymes and the 2-oxoglutarate- and 
oxygen-dependent JmjC KDMs, respectively (97). Recently, a subset of JmjC lysine 
demethylases have also been shown to act as an arginine demethylase on both 
histone and non-histone targets. 
1.2.2 Epigenetic deregulation in cancer 
Epigenetic mechanism can be manipulated to promote a favourable tumourigenic  
environment, for example, CpG islands preceding tumour suppressor genes are often 
hypermethylated in cancer cells which then silences these genes (98). Various tumour 
suppressors including p16 and BRCA1 undergo tumour-specific silencing by 
hypermethylation (99). These genes are involved in cellular processes detrimental to 
cancer development and growth therefore silencing them favours the tumour. 
Promoter hypermethylation also indirectly silences other genes by silencing 
transcription factors. Promoter hypermethylation-induced silencing of transcription 
factors occurs in oesophageal cancer where RUNX3 is silenced and its downstream 
target repressed as a result (100). The mechanism used to target these genes is 
unknown however. One theory is that a growth advantage is gained to cells with certain 
genes hypermethylated therefore are clonally selected (101). Another suggests a role 
for histone marks in tumour specific targeting of de novo methylation as H3K27me3 is 
often found to pre-mark regions that are hypermethylated and these recruit DNA 
methyl transferases, leading to de novo methylation (102). 
Histone modifications can also be hijacked to alter the amount of repressive and active 
markers in the epigenome. For example, cancerous cells exhibit decreased mono-
acetylated and tri-methylated forms of H4 relative to healthy cells (103). Decreased 
acetylation of H3 and H4 is associated with tumourigenesis, along with increased 
H3K9me1 and H3K27me3, and decreased H3K4me3. Mutations in the histone 
octamers also lead to cancerous cells. Histone variants of H2A are able to alter the 
chromatin structure; H2A.Z has a role in gene activation and repression with high 
levels detected in many cancers (104). Epigenetic modifiers genes are also regulated 
in cancerous cells. An epigenetic modifier is a gene that encodes for histone modifiers, 
chromatin remodelers or DNA methylators, for example EZH2 or DNMT1. Mutations 
in these genes will render the gene unreadable so the protein is not translated, or the 
mutation has an oncogenic effect on the proteins function. 
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Mutations affecting a core component of polycomb repressive complex 2 (PRC2), 
histone methyltransferase EZH2, can have differing consequences. One such effect 
reported in non-Hodgkin lymphomas, is that gain-of-function mutations and 
amplifications lead to decreased repressive marker H3K27me3, which is necessary to 
promote lymphoid transformation (105, 106). Moreover, loss-of-function mutations of 
EZH2 are frequently seen in head and neck squamous carcinomas and T cell 
leukaemia (107, 108). This supports the dual function of EZH2 as both an oncogene 
and a tumour suppressor which is contextual based on tissue type. 
Mutations in the DNA methylation machinery are also common. DNA 
methyltransferase 3α (DNMT3A) is mutated by frameshift and point mutations in acute 
myeloid leukaemia (AML) (109), and mutated DNMT3A is shown to be an indicator of 
poor prognosis (109, 110).  Furthermore, DNMT1 is mutated in colorectal cancer with 
mutations in the coding exons leading to inactivation of the gene (111). Mutations in 
chromatin remodelers are widespread in solid tumours too. For example, SMARCB1 
is a regulator of chromatin structure that is deleted or mutated in paediatric rhabdoid 
tumours which leads to tumourigenesis suggesting it normally has a tumour 
suppressor effect (112). This all shows how cancer can manipulate the epigenome 
and epigenetic environment to is advantage to induce tumourigenesis. 
1.3 The roles of histone lysine methyltransferase G9a 
1.3.1 G9a 
G9a or Enzyme Histone Methyltransferase 2 (EHMT2, from here on will be known as 
G9a) is a histone methyltransferase of histone 3 lysine 9 (H3K9), belonging to the SET 
domain containing Su(var) 3-9 family of proteins (113). The SET domain is the proteins 
catalytic centre where which contributes to its methyltransferase activity. G9a also has 
an ankyrin repeat-containing domain which is necessary for protein-protein 
interactions, (113, 114) and two nuclear localisation signals in the N-terminal region 
(115, 116). A representation of these domains is shown in Figure 1.6. G9a also 
contains pre-SET and post-SET domains that was suggested to be required for 
enzymatic activity (71). However, analysis of S. cerevisiae SET domain containing 
proteins shows that none of these contain neither pre-SET or post-SET domains (117). 
Yet, deletion of the pre- and SET domains has been shown to impair heterochromatin 
localisation of G9a suggesting that these are necessary for nuclear translocation 
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(115). G9a has two isoforms through alternative splicing, with the shorter isoform 
(isoform b) missing exon 10 of the 24 exons that encode G9a (118, 119). 
G9a can form a homodimer complexes, however the endogenous preferential is to 
form a heterodimer with G9a-like protein (GLP), a similar histone 3 lysine 9 (H3K9) 
methyltransferase, via their SET domains in a near one-to-one ratio (73). GLP 
possesses the same activities as G9a (73), although studies using methyltransferase-
defective mutants has shown that the enzymatic activity of G9a is more important than 
that of GLP for the in vivo histone methyltransferase function (120, 121). In addition, it 
has been shown that the ankyrin repeat domains of G9a and GLP have differing 
binding affinities towards H3K9me1 and H3K9me2, with G9a preferring to associate 
with H3K9me2 and GLP associating with H3K9me1 (122).  
G9a can mono- or di-methylate H3K9 in euchromatin, the chromosome material 
involved in transcription closest to the centromere. It has also been known to mono-
methylate H3K27, di-methylate H1.2K187, and tri-methylate H3K9 (74, 123). The 
mechanism behind the degree of methylation is determined by key residues in the 
active site of the HMTase. In human G9a, phenylalanine positioned at 1205 allows the 
HMTase to perform di- and tri-methylation, whereas a Tyrosine at the same position 
Figure 1.6  –  G9a isoform structures 
Representation of G9a domain structures of both isoform a and b, adapted from Shankar et 
al, and the Atlas of Genetics and Cytogenetics in Oncology and Haematology 
(http://atlasgeneticsoncology.org/) (118, 124). The denotations are as follows: The Cysteine 
rich region – 12 Cys, ankyrin repeats – ANK, catalytic SET domain with flanking pre- and post- 
SET regions. The site for methylation – Me, nuclear localisation signal – NLS, and the glutamic 







NLS 341 348 
NLS 341 348 




is restrictive and so inhibits tri-methylation (74). This shows that these somatic 
mutations can change the activity of G9a so can act as a switch to different 
methyltransferase activities. 
G9a also regulates gene transcription by catalysing H3K9me2 at the promoter regions 
of genes (58, 75, 125, 126). It has been shown that large regions of chromatin 
associate with H3K9me2 repressive marker in differentiated tissues (127). These 
regions were termed large organised chromatin K9 modifications (LOCKs) and are 
regulated during differentiation, with the size of the LOCKs varying in different cell 
types. 
1.3.2 Non-histone Targets of G9a 
The G9a recognition motif is the seven amino acid string-TARKSTG- found on the tail 
of histone 3 where arginine (R) is paramount to G9a methylation activity (128, 129). 
This motif has also been found in non-histone proteins so G9a can methylate non-
histone targets like p53 at K373 (130), WIZ at K305 and CDYL1 at K135 (131), and 
Reptin at K67 (54, 118, 132). In the case of Reptin, a non-histone chromatin modifier, 
the functional relevance of G9a methylation is well documented. It has been shown 
that nuclear G9a protein levels increase when cells are exposed to hypoxic conditions 
and thus there is an increase in methyltransferase activity and a consequential  
repression of hypoxia regulated genes such as RUNX3, BRCA1, ARNTL, and GATA2 
(133-136). Reptin methylation by G9a occurs under hypoxic conditions too. Methylated 
Reptin can then selectively downregulate target promoters via enhanced binding to 
HIF-1α (132). This has been shown to negatively regulate tumour growth (132). In 
contrast, G9a also methylates chromatin-remodelling factor Pontin under hypoxia. 
This in turn activates a different subset of HIF1α target genes that are involved in 
oncogenesis and cell survival (137, 138). All together this shows that G9a methylation 
of non-histone targets also has an activating or repressing potential similar to its 
histone targets. G9a also methylates other transcription factors which impairs their 
transcriptional activity. For example, G9a methylates transcription factor C/EBP β, at 
K39 to stop the activation of myeloid genes. Inactivation of G9a is able to rescue this 
and reactivate myeloid genes (139).  
Interestingly, G9a also has a G9a recognition motif within its N-terminus which can be 
automethylated. This does not affect the catalytic ability of G9a and resembles 
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H3K9me3 in structure (118). This enables HP1γ (or CBX3) to recognise G9a as a 
binding partner and thus form the ternary complex GR-G9a/GLP-HP1γ to activate a 
subset of glucocorticoid genes (140). HP1 also interacts with DNA methyltransferase 
DNMT1 to silence gene promoters and so suggests G9a-HP1 complex can act as a 
scaffold to propagate gene repression. Moreover, WIZ protein has been shown as a 
core subunit of a G9a/GLP complex along with ZNF644, both of which contain multiple 
zinc finger motifs that recognise DNA sequences (141). These zinc finger proteins can 
then target the G9a/GLP dimer to chromatin to regulate transcriptional repression of 
genes such as ROCK1 and DIP2C (141).  
G9a can also act as a co-activator independent of its methyltransferase activity. It has 
been shown to cooperate with nuclear receptor coactivators GRIP1, CARM1 and p300 
(142). Via its ankyrin repeat domain, G9a binds to the N-terminus of GRIP1 and this 
forms a scaffold complex to activate downstream targets. However, it was shown that 
G9a mutants with inactive methyltransferase domains had reduced activity at lower 
levels of G9a expression suggesting that whilst not required for coactivator activity, 
the methyltransferase activity may contribute to coactivator function (142). This all 
suggests that G9a can act as a transcriptional switch to activate or repress gene 
transcription depending on its binding partner. This is summarised below in Figure 1.7, 
along with examples of other activated and repressed target genes. 
Figure 1.7 – Suggestion that the binding partner(s) of G9a determines its function as a 




1.3.3 G9a in cancer 
G9a has been implicated in cancer tumourigenesis due to overexpression in various 
cancers, including breast, lung, and head and neck (143) (Table 1.4). Overexpression 
has also been associated with poor prognosis (144) and there is a correlation with 
increased methylation and the silencing of tumour suppressor genes (116, 145). It has 
been shown that in breast cancer, G9a regulates tumour suppressor p53 by di-
methylating at position K373 thus inactivating it (130), and the metastasis suppressor 
genes DSC3 and MASPIN were reactivated upon G9a inhibition and depletion (145). 
Moreover, in ovarian cancer G9a activity promoted the suppression of tumour 
suppressors CDH1, DUSP5, SPRY4, and PPP1R15A (146). This evidence points 
towards G9a as a potential target for the re-expression of important tumour suppressor 
genes. In gastric carcinoma the depletion of G9a suppressed cell proliferation, and 
increased apoptosis by significantly promoting pro-apoptotic factor BAX (147). 
 
G9a overexpression in Cancer Reference 
Oesophageal squamous cell carcinoma (ESCC) (144) 
Hepatocellular carcinoma (130, 148) 
Aggressive lung cancer (130, 143, 149) 
Aggressive ovarian carcinoma (130, 150) 
Breast cancer (143, 151) 
B cell acute lymphoblastic leukemia (ALL) (130, 152) 
Colon carcinoma (130) 
Melanoma (130) 
Prostate carcinoma (130) 
Head and neck cancer (153) 
Colorectal cancer (154) 
Bladder carcinoma (149) 
Table 1.4 – Cancers that are suggested to be influenced by G9a overexpression 
 
In addition, it was shown in breast cancer that effective gene re-expression 
necessitated the inhibition of G9a and another histone methyltransferase, and 
Polycomb Repressive Complex (PRC2) member, EZH2. For example, dual depletion 
of both G9a and EZH2 dramatically increased SPINK1 mRNA when individual 
depletion had no effect (155). This dual inhibition was also shown to increase growth 
inhibition over only G9a or EZH2 single inhibition (155). It is known that PRC2 and 
G9a physically interact and share several genomic targets that encode developmental 
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regulators such as HOXC13 and SIX1, and they both colocalise at the promoters for 
neuronal differentiation genes too by forming a tertiary complex with neuronal 
regulator REST (156-158). It is suggested that G9a-mediated H3K27 mono-
methylation enhances PRC2-mediated trimethylation as G9a is necessary to increase 
PRC2 activity, especially as EZH2, HMT part of the PRC2, recruitment and H3K27me3 
trimethylation are impaired (156). This all suggests that there is an interplay between 
the H3K9me2/3 repressive markers governed by G9a and the H3K27me3 governed 
by EZH2, and that it is necessary to deplete both to reactivate co-regulated genes.  
1.3.4 G9a small molecule inhibitors 
To date, there are many types of G9a inhibitor with the first, BIX-01294, initially 
described in 2007 via high throughput biochemical screening (159). BIX-01294, a 
diazepin-quinazolin-amine derivative (75), consists of a central quinazoline ring linked 
to a seven-membered diazepane ring and a benzylated six-membered piperidine ring 
(160). BIX-01294  has been used to probe G9a in cellular reprogramming (161, 162), 
and to inhibit G9a to reactivate latent HIV-1 (163). In addition, BIX-01294 has been 
used to show that G9a mediates methylation of Oct-3/4 promoter (164).  
However, whilst originally being described as being G9a-specific, it has been 
suggested that BIX-01294 is actually more potent against GLP and acts as a 
competitive inhibitor of N-terminal peptides of Histone 3 (160, 165). Furthermore, BIX-
01294 is now known to be toxic in cellular assays, with a study suggesting 
concentrations above 4.1µM is likely to cause off-target toxicity (166). This raises the 
possibility that from current published work with G9a inhibition via small molecule 
inhibitor BIX-01294 may partly attributable to off-target effects of the BIX-01294 drug 
and not a true effect of G9a inhibition.  
Because of these off-target effects of BIX-01294, a new high-quality chemical probe 
with an enhanced ratio of toxicity to functional potency was necessary (167). There 
are a vast number of different small molecule inhibitors available. Vedadi et al 
optimised the 2,4-diamino-6,7-dimethoxyquinazoline scaffold template to discover 
new chemical probes for G9a and GLP. UNC0638 was reported as a potent and 
selective probe for G9a and GLP which is less toxic and more selective than BIX-
01294 (168). However, this is not suitable for animal studies due to its poor in vivo 
pharmacokinetic (PK) properties (168). Therefore, Liu et al aimed to optimise the PK 
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properties of quinazoline series of inhibitors to generate UNC0642 (169). UNC0642 
has improved pharmacokinetic properties that are non-toxic in 2D cell growth assays 
but reduced colony formation of pancreatic adenocarcinoma cells (169). UNC0638 
and UNC0642 act as competitive substrate inhibitors, thus blocking the SET domain 
from acquiring methyl groups from SAM cofactor. 
Chemical probe UNC0646 is a close analogue of UNC0638 and has been suggested 
to have an outstanding toxicity/function ratio in three cancer cell lines (170). Another 
inhibitor A366, is chemically distinct however works in the same manner of substrate 
competition (171). Recently, four novel SMI of G9a were discovered, with DCG066 
having the best activity (172). DCG066 has a similar activity to BIX01294 (1.7±0.1μM 
and 3.9±0.3μM respectively in K562 leukaemia cell line) yet has a new structure 
allowing for further inhibitor development (172).  
1.4 What is Neuroblastoma? 
1.4.1 Origin 
Neuroblastoma is a paediatric cancer of the sympathetic nervous system and is one 
of the most frequent extracranial solid tumours, as originally described by James 
Wright (173).  It arises from developing neural crest cells that will give rise to the 
peripheral and enteric nervous systems, amongst others (174). These cells develop in 
response to extracellular signals such as growth factor Bone Morphogenetic Protein 
(BMP), and Shh. Furthermore, these neural crest-derived cells are highly migratory 
due to undergoing EMT shortly after induction. Neuroblastoma is responsible for 15% 
of childhood cancers deaths despite an incidence rate of 6% of all childhood cancers 
(175) with 90% of cases are diagnosed by the age of 5 (176) and 48% of patients have 
a metastatic form at diagnosis (177). 
1.4.2 Clinical staging 
There are various stages of neuroblastoma which are defined by two staging systems: 
and 1) The International Neuroblastoma Staging System (INSS) (Table 1.3), and 2) 
The International Neuroblastoma Risk Group Staging System (INGRSS) (Table 1.4). 
The INSS was developed in 1988 (178) is still the most used by cooperative groups 
(179) however is not suitable for pre-treatment risk classification of patients as this 
staging is based on the extent of tumour removal (180) suggesting that the same 
tumour can be classified as INSS stage 1 or 3 depending on the extent of surgical 
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excision (179). Thus in 2004, several major cooperative groups formed the 
International Neuroblastoma Risk Group Task Force and developed the INGRSS. This 
is designed for staging prior to surgery or treatment. 
Neuroblastoma patients are stratified into risk groups at diagnosis with low-, 
intermediate-, or high-risk statuses. The factors that help contribute to the risk status 
are shown in table 1.5 (181). As shown in Figure 1.8, risk stratification schemes have 
successfully determined the outcomes of patients within these three groups, along 
with a dramatically reduced event-free survival of <50%. This suggests that targeting 





Figure 1.8 – Kaplan-Meier curve showing the survival of neuroblastoma patients based 










Table 1.3 – INSS Tumour Stages. Adapted from Brisse et al (179) 
 










Table 1.5 – Factors associated with high-risk in neuroblastoma 
 
Stage Description 
1 Localized tumour excision, with or without microscopic residual disease 
2a Localized tumour with incomplete gross excision 
2b Localized tumour with or without complete gross excision 
3 Unresectable unilateral tumour infiltrating across the midline (beyond the 
opposite side of the vertebral column) with or without regional lymph node 
involvement, or localized unilateral tumour with contralateral regional 
lymph node involvement, or midline tumour with bilateral extension via 
infiltration (unresectable) or lymph node involvement 
4 Any primary tumour with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin, and/or other organs (except as defined for stage 
4S disease) 
4S Localized primary tumour with dissemination limited to skin, liver and/or 
bone marrow (limited to infants <1 year of age, marrow involvement 
<10% of total nucleated cell 123I-metaiodobenzylguanidine scan findings 
negative in the marrow) 
Stage Description 
L1 Localised tumour not involving vital structures and confined to one body 
compartment 
L2 Loco-regional tumour with presence of one or more IDFRs 
M Distant metastatic disease (except stage MS tumour) 
MS Metastatic disease in children younger than 18 months with metastases 
confined to skin, liver, and/or bone marrow 
High risk factors 
Patient age 
Stage of disease 
Presence or absence of MYCN-amplification 
Tumour cell ploidy 
Chromosomal aberrations 
Histopathological appearance of the tumour 
Age—younger children have better survival rates 
25 
 
1.4.3 Epigenetics in neuroblastoma 
Somatic mutations are rare in neuroblastoma, so it is suggested that chromatin 
modification and unusual epigenetic regulation plays a key role in neuroblastoma 
cancer development (183). In neuroblastoma, there are several tumour suppressor 
and apoptosis-driving genes that are hypermethylated. These include the promoters 
for RASSF1A and CASP8 (Caspase-8) whose silencing is well established and 
associated with poor prognosis (184). In addition to gene silencing, the expression of 
epigenetic writers can also be manipulated to fit the cancer’s needs. In 
neuroblastoma the upregulation of Polycomb protein histone methyltransferase 
EZH2 is necessary to maintain an undifferentiated and poor prognostic state by 
increasing the repressive marker H3K27me3 on tumour suppressor proteins such as 
CASZ1 (185).  
1.4.4 ALK and TERT amplification  
There are numerous chromosomal abnormalities associated with neuroblastoma, with 
deletions of chromosomes 1q and 11q, gain of 17q, and MYCN-amplification on 2p 
(186). ALK (Anaplastic Lymphoma Kinase) is a member of the insulin receptor 
superfamily of receptor tyrosine kinases. The discovery of activating mutations in ALK 
oncogene in both hereditary and sporadic neuroblastoma represents a druggable 
target. Mutations in ALK are frequently observed in poor prognostic MYCN-amplified 
neuroblastoma. 
ALK oncogene was initially identified as a gene that fused with nuclear protein NPM 
(Nucleophosmin) through 2;5 chromosomal translocation that occurs in most 
anaplastic large-cell non-Hodgkin’s lymphoma (187). ALK ligands include pleiotrophin 
(PTN) and midkine (MDK) both of which are secreted growth factors (188, 189). ALK 
was considered an orphan receptor until recently when ALKAL1 and ALKAL2 were 
shown to be bona fide ligands (190). These bind to ALK to activate downstream 
mitogen-activated protein kinase (MAPK) pathway and induces insulin receptor 
substrate 1 (IRS1) phosphorylation respectively. The latter results in  MAPK and 
phosphoinositide 3-kinase (PI3K) activation (191, 192). It was suggested that ALK 
could potentiate oncogenic activity in neuroblastoma cells when its expression level 
exceeded a threshold (193). ALK can be amplified or it may possess gain of function 
mutations at the tyrosine kinase domain, with R1275Q and F1174L the most common 
(194, 195). These mutations disrupt the autoinhibitory function of ALK to keep ALK 
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constitutively active. MYCN and ALK synergistically cooperate to induce 
neuroblastoma (186, 196). 
Telomere shortening is common to normal cells to restrict lifespan; cancer cells can 
preserve their telomere length by alternative lengthening of telomeres (ALT) or 
activation of telomerase reverse transcriptase (TERT). TERT is activated by promoter 
mutations (197) and upstream rearrangements, with these rearrangements in 
approximately 23% of examined high-stage NB (198). Alteration in TERT was 
independent of MYCN-amplification and is associated with poor prognosis (198). 
1.4.5 High-risk transcription factor MYCN 
1.4.5.1 MYCN in normal cells 
MYCN is a classic oncogene transcription factor that is part of the MYC family. MYC 
family members are basic helix-loop-helix transcription factors who dimerise with MAX. 
This family is known to regulate genes associated with apoptosis, cellular proliferation, 
and differentiation. Upon binding to target promoters, MYCN recruits histone 
acetylation complexes (HATs) like TRRAP which contains HATs GCN5/PCAF or 
TIP60 to maintain an open chromatin state (199). Located in chromosome 2p24, 
MYCN was initially discovered as a paralog of C-MYC (MYC) when gene mapping in 
neuroblastoma cells discovered MYCN as a homologous proto-oncogene like MYCN 
(200). As a result, they are functionally interchangeable with MYCN expression able 
to replace MYC expression in developing murine models (201). Soon after, a third 
MYC family member MYCL was detected as being amplified in small cell lung cancers 
(202). 
MYCN is expressed during embryogenesis in pre-B cells, kidney, intestine, and the 
fore and hindbrain. The developing brain is where the highest expression of MYCN is 
found and after embryonic development, MYCN is then downregulated (203). MYCN 
plays an essential role in normal brain development to drive the expansion of neuron 
precursors populations. These are derived from neuronal progenitor cells of the 
developing forebrain and hindbrain (204). In neural crest cells with enhanced MYCN 
expression, differentiation was downregulated in favour of the proliferation of immature 
neuronal precursors (205). Constitutive deletion of MYCN is embryonic lethal (206), 
and mutations causing MYCN inactivation lead to Feingold syndrome (207). This a 
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characterised by microcephaly, limb abnormalities, and learning difficulties, all of 
which can be attributed to the perturbance of normal neural development. 
 
1.4.5.2 MYCN in neuroblastoma and other cancers 
MYCN-amplification is defined by 10-500 copies of the gene and is characterised in 
around 25% of the most aggressive neuroblastomas. It is considered to a robust 
prognostic biomarker for determining outcome as it is strongly associated with 
prognosis (208-211). This is visualised in the Kaplan-Meier curve below, Figure 1.9. 
The difference between the survival probabilities between patients with low (red) and 
high (blue) MYCN-amplification is drastically significant demonstrating how much of a 
risk factor MYCN plays.  
Being a transcription factor, MYCN predominantly upregulates gene transcription by 
binding to specific DNA sequences called E-boxes (5’-ACCGTG-3’) to initiate gene 
transcription (212). These targets include ALK receptor tyrosine kinase which 
promotes proliferation and cell survival by activating downstream targets AKT/ERK 
(213-215). In addition, MYCN also upregulates proto-oncogenic transcription factor 
High mobility group A1 (HMGA1) which is overexpressed as a result (216, 217).  
MYCN can also act to repress gene transcription. Overexpression of MYCN down 
regulates interleukin-6 (IL-6) (218), and endothelial cell proliferation inhibitor activin A 
(219-221). This downregulation helps to drive tumourigenesis and proliferation, hence 





Figure 1.9 – Patients with MYCN-amplified tumours have a significantly decreased 
overall survival probability 
Using the Genomic Analysis and Visual Platform R2 (http://r2.amc.nl), a Kaplan-Meier survival 
curve in neuroblastoma shows the relationship between high MYCN mRNA expression and 
poor prognosis. The database used was SEQC- 498 which is derived from RNA sequencing 
data of 498 neuroblastoma (222). 
 
1.4.6 Regulation of MYCN 
MYCN is regulated by both transcriptional and translational mechanisms. MYCN has 
been shown to be transcriptionally regulated by the E2F family of transcription factors. 
Using chromatin immunoprecipitation (ChIP) E2F-1, 2, and 3 all bound to the proximal 
MYCN promoter in MYCN-amplified neuroblastoma and inhibition of E2F activity was 
also able to reduce MYCN expression (223). Translational regulation of MYCN has 
been shown in neuroblastoma. Activated H-Ras through an oncogenic mutation can 
promote MYCN accumulation by accelerating MYCN translation (203, 224).  
MYCN protein is turned-over during the interphase stage of mitosis. The half-life of 
MYCN is known to be very short (225) so the turnover occurs quickly. This degradation 
allows for neuronal precursors to undergo differentiation (226). This degradation event 
occurs through phosphorylation events at serine 62 and threonine 58, and subsequent 
ubiquitination and degradation by the proteasome. This proteasomal degradation is 
disrupted in MYCN-amplified neuroblastoma to help keep the cells in a highly 
proliferative state. Aurora kinase A is overexpressed in neuroblastoma cells which 
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hinders the interaction between phosphorylated threonine 58, and the ubiquitin ligase 
FBXW7 so MYCN cannot be ubiquitinated (227, 228). MYCN protein has been shown 
to be stabilised by other PTMs such as methylated arginine by protein arginine 
methyltransferase 5 (PRMT5) which increases MYCN half-life (229).  
1.4.7 MYCN targets 
1.4.7.1 MYCN and the cell cycle 
MYCN regulates the cell cycle by shortening the time to progress through the cell 
cycle, specifically reducing the length of the G1 phase (208). MYCN accomplishes this 
by downregulating a subset of cyclin-dependent kinase inhibitors (CKIs), a class of 
proteins that negatively regulate progression through the cell cycle. MYCN represses 
the expression of p21CIP1, a member of the Cip/Kip family of CKIs (230), by forming a 
complex with other transcriptional regulators, such as MIZ-1 and SP1 (231). This 
promotes cell growth and tumourigenesis. 
1.4.7.2 MYCN and apoptosis  
MYCN can regulate apoptosis by repressing pro-apoptotic genes. For example, MYCN 
elevates transcription of proto-oncogene MDM2. MDM2 is a p53 suppressor and 
inhibits p53-mediated apoptosis (232) which is discussed further on. In addition, 
methylation of (CASP8) promoter has also been observed in neuroblastoma at a high 
frequency although this is suggested to be independent of MYCN-amplification status 
(184, 233). MYCN can also repress nerve growth factor receptor (NGFR/P75NTR), a 
receptor that binds to neurotrophins. It is suggested that NGFR contain death domains 
in intracellular regions that may induce neuronal cell death; NGFR expression is 
strongly downregulated in MYCN-amplified neuroblastoma (234, 235). Depletion of 
MYCN was shown to re-express NGFR and sensitise the cells to NGF-mediated 
apoptosis (231). 
However, paradoxically MYCN also represses genes that are characterised by an anti-
apoptotic function. For example, MYCN has been shown to repress Galectin-3, an 
anti-apoptotic factor overexpressed in breast carcinoma cells resistant to cisplatin-
induced apoptosis (236, 237). Furthermore, when galectin-3-negative Burkitt 
lymphoma cells were transfected with a plasmid expressing Galectin-3 there was an 
increase in resistance to anti-Fas-induced cell death (238). In addition, increased 
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MYCN sensitises cells to chemotherapeutic agents like doxorubicin so can increase 
chemotherapy-induced apoptosis (239).  
1.4.8 MYCN and chromatin modifications 
MYCN is responsible not only for direct regulation of transcriptional activation or 
repression but can also independently regulate the modification of chromatin through 
maintaining the chromatin in an open state (240), and deletion of N-MYC in neuronal 
progenitor cells leads to a closed chromatin (241). 
MYCN can also interact with histone modifiers to regulate gene transcription. For 
example, MYCN physically interacts with PRC2 histone methyltransferase EZH2 via 
Myc box domain 3 and this complex supresses expression of tumour suppressor CLU 
(242). As well as recruiting HATs and interacting with EZH2, MYCN can also interact 
with histone modifier DOT1L. MYCN has been shown to directly bind to the promoter 
of DOT1L gene to upregulate DOT1L promoter activity. Furthermore, DOT1L can also 
bind directly to MYCN protein to drive H3K79 di-methylation and activates target genes 
such as ODC1 and E2F2 to assist proliferation (243). 
1.4.9 Targeting MYCN – Drugs and synthetic lethality 
As a high-risk factor and oncoprotein involved in cell proliferation and tumourigenesis, 
MYCN is an obvious therapeutic target. However, due to its helical structure, there are 
no surfaces for ligands to bind making MYCN directly undruggable (176). Therefore, 
alternative methods have been developed to target MYCN and inhibit its activity. 
Two genes are classed as synthetic lethal if mutation of two genes simultaneously is 
lethal (244). Therefore, targeting a synthetic lethal gene via pharmacological inhibitors 
is a potential therapeutic technique as it targets a functional interaction that is found in 
cancer cells (245). Figure 1.6 illustrates this. Moreover, there are combinations of gene 
mutations that can lead to non-lethal growth impairment, termed synthetic sickness.   
The concept was developed from genetic studies in D. melanogaster and D. 
pseudoobscura (246, 247), and S. cerevisiae models (248), where combinations of 
non-allelic genes were lethal despite homozygous parents being viable. This is an 
example of Figure 1.6A. There are many examples of synthetic relationships across 
various cancer types. For example, breast cancers can be driven by mutations in 
BRCA1 or BRCA2 tumour suppressor genes, which impairs DNA double-strand break 
repair mechanisms (249). However, cells with BRCA1 or BRCA2 dysfunction are more 
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sensitive to pharmacological inhibition of Poly(ADP-ribose) polymerase (PARP), a 
base excision repair enzyme involved in the pathway for repair of single-strand DNA 
breaks. This results in the chromosomal instability, cell cycle arrest, and subsequent 
cell death via apoptosis as the cell accumulates DNA lesions that cannot be repaired 
(250, 251). This is an example of the type of synthetic lethality shown in Figure 1.10C 
and highlights the synthetic lethal relationship between BRCA1 and BRCA2, and 
PARP inhibition which is the first example of a successful synthetic lethal therapy that 
is used in clinics. 
MYCN-amplified neuroblastoma is an example of overexpression (Figure 1.10A). 
There have been many examples of synthetic lethal partners of MYCN in 
neuroblastoma published such as Aurora kinase A, PRMT5, and Cyclin dependent 
kinase 2 (CDK2) (227, 229, 252). For example, Aurora kinase A inhibitors target 
MYCN protein stability as aurora kinase A binds to MYCN to shield it from degradation. 
Aurora kinase A inhibitor Alisertib (MLN8237) can cause the depletion of MYCN in 
neuroblastoma cell lines by blocking the ability of Aurora kinase A to protect MYCN 
from FBXW7-mediated degradation (227, 253). Therefore, this therapeutic treatment 
can suppress MYCN protein levels and reduce cell growth in MYCN-amplified 
neuroblastoma. MYCN can also be targeted by controlling its activation ability. MYCN 
heterodimerises with MAX to recognise the E-box domains on target promoters 
therefore disrupting this interaction would effectively stop the transcriptional activity of 
MYCN. Small molecule 10058-F4 has been shown to interfere with MYCN/MAX 
dimerisation and reduce the tumorigenic potential of MYCN-amplified neuroblastoma 
as a result (254). However, 10058-F4 is rapidly metabolised and thus this SMI is not 
a suitable therapeutic agent (255). 
Arginine methyltransferase PRMT5 can di-methylate MYCN to increase protein 
stability. When PRMT5 was depleted, MYCN protein decreased which lead to 
apoptotic cell death (229). Moreover, BET (bromodomain and extra-terminal domain) 
inhibitors JQ-1 and OTX-015 have been shown to target MYCN-driven transcription 
(256, 257). In addition, neuroblastoma cells are sensitive to histone 3 lysine 27 
(H3K27) demethylase inhibitor GSK-J4 which inhibits ubiquitously transcribed 
tetratricopeptide repeat, X chromosome (UTX), and histone demethylase Jumonji D3 





Figure 1.10 – Synthetic lethality model based on O'Neil et al (245).  
A – The loss or the inhibition of either of the proteins encoded for by gene A or gene B alone, 
or the overexpression of gene A is viable cancer cells. B – Mutation of protein encoded by 
gene B in cells with mutation in gene A results in synthetic lethality. C – Pharmacological 
inhibition of the protein encoded for by gene B in cells with a mutation in gene A results in 
synthetic lethality. D – Pharmacological inhibition of the protein encoded for by gene B in cells 
overexpression of gene A results in synthetic lethality and the subsequent death of the cell. 
The thicker arrow denotes increased gene expression. The star shape denotes a mutation. 
Red crosses denote pharmacological inhibition. Viable cells are depicted as ovals, and lethal 




1.4.10 G9a and neuroblastoma 
G9a and neuroblastoma has not been well characterised with only three papers 
published thus far- 1) Ding et al (259), 2) Lu et al (260), and 3) Ke et al (261). This 
literature does suggest that G9a is a key driver of proliferation as inhibition with BIX-
01294 consistently repressed cell proliferation in a variety of tested neuroblastoma cell 
lines. However, only Ding et al looked at the effect of G9a depletion on proliferation to 
confirm that BIX-01294 was targeting G9a (259).  
However, this is where the similarities between the results of these papers stop 
suggesting that these results need re-confirming to validate their reliability. For 
example, when assessing if cell cycle arrest occurs following G9a inhibition, Ding et al 
immunoblot for two cell cycle genes cyclin A2 and cyclin B2 after 5µM BIX-01294 in 
SHEP-1 over the course of four days. They see a consistent decrease in these proteins 
with both depleted after three days thus suggesting there is cell cycle arrest. Lu et al 
however perform flow cytometry for cell cycle analysis alongside probing for cyclin D1. 
LA1-55n were treated with 2.5μg/ml (4.16µM) BIX-01294 over 24 hours and see no 
change in cell cycle progression or expression of cell proliferation related genes. Ke 
et al uses a wider range of cell lines with SK-N-AS, BE(2)-C, SK-N-DZ, SK-N-F1, and 
SHEP1 treated with 5µM BIX-01294 for 2-4 days. They show consistent increases in 
G1 phase cell cycle arrest along with downregulation of cyclinD1, CDK4 and CDK6 in 
all cell lines suggesting G9a inhibition does cause cell cycle arrest to inhibit 
proliferation. Therefore, these papers seemingly contradict one another with their 
overall conclusions alongside having no standard controls with which to compare 
these results.  
Furthermore, in the context of cell survival, Ding et al suggests that G9a inhibition 
triggers autophagic cell death, Lu et al suggests G9a inhibition triggers apoptotic cell 
death, and Ke et al again suggests G9a inhibition leads to autophagy but show no cell 
death data. Moreover, Ke et al contradicts Ding et al by suggesting that no apoptosis 
is shown in their study. Therefore, these papers seem to agree that there is cell death 
occurring following G9a inhibition yet disagree on the method of this death. 
Conversely, Ding et al also shows the effect of increased G9a expression by 
overexpressing G9a in SHEP1 cells. The cells with more G9a expression had 
increased cell proliferation and expression of cell cycle progression genes. Moreover, 
34 
 
overexpression of G9a activated genes involved in serine biosynthesis thus increasing 
serine production. This suggests a mechanistic reason for G9a promoting tumour 
survival and proliferation and is further evidence of the gene activator and repressor 
role of G9a. 
The effect of G9a on MYCN regulation has only been suggested by Lu et al. They 
suggest that LA1-55n cells treated with 5µg/ml (8.33µM) BIX-01294 for 24 and 48 
hours displays a significant change in MYCN mRNA expression. Moreover, LA1-55n 
cells were treated with 1, 2.5, and 5µg/ml (1.67, 4.17, and 8.33 µM respectively) for 
24 hours show a reduction in MYCN protein in a dose dependent manner. The other 
papers do not test the effect of G9a on MYCN or other potential risk factors, for 
example ALK. 
The main issue with these studies however is that these papers all inhibit G9a using 
small molecular inhibitor BIX-01294. BIX-01294 is a known specific inhibitor of G9a 
and a non-competitive with cofactor SAM (75) As previously mentioned, BIX-01294 
has been shown to toxic above concentrations of 4.1µM (166), therefore the results 
and effects suggested by these studies may just be an artefact of off-target toxicity. 
This suggests that these studies need to be repeated with a more reliable small 
molecule inhibitor to truly assess G9a’s involvement in neuroblastoma. 
 
1.5 Aims of this research 
In this thesis, the role of Histone methyltransferase G9a will be explored in MYCN-
amplified neuroblastoma. MYCN regulates the activation and repression of its targets 
with the aid of histone modifiers such as histone deacetylases and methyltransferases. 
This cooperative mechanism is a potential target for disrupting MYCN stabilisation. 
Specific aims are to: 
• Examine G9a as a potential oncoprotein in neuroblastoma 
• Assess the efficacy of targeted G9a small molecule inhibitors in neuroblastoma 









Materials and methods  
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2.1 Neuroblastoma Cell lines 
The Neuroblastoma cell lines used for this study were derived from different sources, 
either as gifts from other laboratories or purchased from cell banks. The known 
genotype characteristics of are summarised in Table 2.1. These were used as in vitro 
models in the study. 
Kelly 
MYCN-amplified human neuroblastoma cell line donated from Louis Chesler's lab in 
The Institute of Cancer Research (ICR). Established from bone marrow metastasis of 
a 1-year old female with stage 4 (262). 
LAN-1 
MYCN-amplified human neuroblastoma cell line donated from Louis Chesler's lab in 
the ICR. Established from bone marrow metastasis of a 2-year-old male with stage 4 
(263). 
IMR-32 (IMR32) 
MYCN-amplified human neuroblastoma cell line donated from Louis Chesler's lab in 
the ICR. They are derived from a primary tumour site in the abdomen of a 1-year-old 
male (264).   
SH-SY5Y (SHSY5Y) 
MYCN non-amplified human neuroblastoma cell line donated from Louis Chesler's lab 
in the ICR. It carries a single copy of MYCN. This cell line derived from the parental 
cell line, SKNSH which was established from bone marrow metastasis of a 4-year-old 
female with stage 4 (265). 
SK-N-AS (SKNAS) 
MYCN non-amplified human neuroblastoma cell line donated from Louis Chesler's lab 
in the ICR. established from bone marrow metastasis of an 8-year-old female with 
stage 4 disease (266).  The cells express wild type p53 (267).   
SK-N-BE(2)C (BE2C) 
MYCN-amplified human neuroblastoma cell line donated from Louis Chesler's lab in 
the ICR. Established from parental cell line SK-N-BE(2). The parental cell line was 
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established in 1972 from the bone marrow biopsy of a two-year-old male with stage 4 
neuroblastoma and has chromosome 1p deletion and alterations in chromosome 17 
(266), and carries p53 mutation (C135F) (268).   
NGP 
MYCN-amplified human neuroblastoma cell line established from lung metastasis of 
a two-year-old male with chromosome t(1p) alterations (262, 266). The cell 
morphology displays neuronal-like elongated cells (N-type) (267).  The cells also 
harbor wild type p53 protein (269). 
GI-ME-N (Gimen) 
MYCN non-amplified human neuroblastoma cell line that carries a single copy MYCN. 
This is from the bone marrow metastasis of a two-year-old female with stage 4 (270). 
Gimen has 1p deletion and express wild type p53 (271).  
SHEP-21N 
SHEP-21N cells are engineered by Manfred Schwab from non-MYCN-amplified SH-
EP. The cell line was established by transfection of a CMV construct fused with human 
MYCN; expression is controlled by a tetracycline-off system (272). This enables the 
effect to be determined in two cell lines that only differ in their MYCN-amplification 
genotype. 
Disease free cells 
RPE-1 
RPE-1 is an immortalised retinal pigment epithelial cell line, derived by transfecting 
RPE-340 cell line with pGRN145 hTERT-expressing plasmid (273). These cells were 
kindly donated from Grant Stewart's laboratory in Birmingham. 
NF-TERT 
NF-TERT is an immortalised human fibroblast cell line that derived from a skin biopsy. 
This cell line was immortalized with hTERT pBAbe retro puro. These cells were kindly 


























Table 2.1 – Characterisation of neuroblastoma cell lines 
For MYCN status: (+)  MYCN-amplified, (-) MYCN-unamplified, HSR- homogeneous staining region, SC- single-copy, DM- double minute. 
For ALK amplification: (+): ALK-amplified, (-) ALK-unamplified, blank; unknown. 
For mutation statuses: WT; wild type, Mut; mutated. 































































WT (-) WT (267, 271, 286, 291) 
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2.2 Cell Culture 
Media for neuroblastoma and normal fibroblast cell culture 
Neuroblastoma and disease-free cell lines were grown either in Dulbecco’s modified 
eagle’s medium: nutrient mixture F-12 (DMEM:F12) – LAN-1, IMR32, SHSY5Y, 
SKNAS, BE2C, RPE-1, or RPMI 1640 (Gibco) as detail in table 2.2. Each were 
supplemented with 10% (v/v) foetal bovine serum (FBS) (Life technologies), 2mM L-
glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1% (v/v) non-essential 
amino acids, unless otherwise stated. All cells were cultured as adherent monolayers 
at 37˚C with 5% CO2. 
Media for S21N neuroblastoma 
The SHEP-21N cells were maintained in the presence of tetracycline 1:2000. They 
were cultured in RPMI 1640 (Gibco), supplemented with 10% (v/v) tetracycline-free 
FBS (Life technologies), 2 mM L-Glutamine, 100 U/mL penicillin, 0.1 mg/mL 
streptomycin, and 1µg/mL tetracycline. 
Cell line maintenance 
All cell lines were grown as adherent monolayers and incubated at 37ºC and 5% CO2 
in a humidified incubator. Media was replaced every two to three days. 
Cell Subculture 
When cells reached 80 to 90% confluency, they would be passaged. Media was 
aspirated, and cells washed once in DPBS (5mL per T75) (Gibco). This was then 
removed, and trypsin was added (3mL per T75) and incubated at 37ºC until the cells 
detached from the flask. Fresh media was then added to deactivate the trypsin (7mL 
per T75) and this suspension was collected in a 25mL universal and centrifuged for 
three minutes at 1500 rpm. The supernatant was then removed, and cells 
resuspended in 10mL fresh media. The resuspended cells were placed in a new 
culture flask at a ratio of 1:10 (volume of cell suspension: total volume of media) and 





Cell counting (live and apoptotic) 
Cell-counts and cell viability were assessed using the Countess-automated cell 
counter (Thermo Fisher Scientific). 10µL cell suspension was mixed with 10µL trypan 
blue dye (Thermo Fisher), and 10µL of this mixture was then added to the disposable 
counting slides (Thermo Fisher). The total concentration of cells, concentration of live, 
concentration of dead cell population (all were per mL) and percent viability of the total 
cell population were obtained. The cell counts could then be analysed for statistical 
significance, n ≥ 2. 
Drug treatment with small molecule inhibitors 
Cells were seeded the night before. Drug was then diluted in fresh media which 
replaced the old media. Drugs were all diluted in DMSO and stored at-20̊C. Kelly cells 
were treated with 2.5 to 5µM of UNC0638. All other cell lines were treated with 10µM 
unless stated separately. Cells were treated for 24 or 72 hours. UNC0642, A366 and 
UNC0646 were also used in MTT viability assays from 20µM. 
MTT cell viability assay 
Cell lines were seeded in 96 well plate between 5000 to 15,000 cells per well in 80µL. 
The next day, 20µL of 5x the highest concentration of drug was added to triplicate 
treatments. After 72 hours,  10 µL of MTT (5 mg/mL) (Sigma) was added and incubated 
for a further 3 hours. Then 50 µL of SDS lysis buffer is added and the cells were 
incubated overnight at 37ºC.  
The plates are then read the next morning with absorbance values at wavelengths 
570nm and the reference wavelength of 650 nm, using SpectraMax 190 plate-reader 
(Molecular Devices).  The percentage of survival was calculated by dividing the 
absorbance values of each well with absorbance value of the vehicle control and 
multiplying them with 100. The dose-response graphs were drawn using GraphPad 




2.3 Molecular Biology methods 
RNA extraction 
The RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) following the 
manufacturer’s instruction. To lyse the cells, 350µL of RLT lysis reagent with 3.5µL β-
mercaptoethanol was used. Mixture was vortexed for 30 seconds and lysate 
transferred to a gDNA Eliminator spin column. This was centrifuged for 30s at ≥8000g 
(≥10,000 rpm). 350µL 70% (v/v) ethanol was then added to the flow-through, mixed, 
and 700µL transferred to RNeasy spin column. This was centrifuged for 15s at ≥8000g 
and flow-through discarded. 700µl buffer RW1 is then added to the RNeasy Mini spin 
column and centrifuged for 15s at ≥8000g and flow-through discarded. Next, 500µl 
buffer RPE is added to the RNeasy spin column. This is centrifuged for 15 s at ≥8000g 
and the flow-through discarded. This step is then repeated but the columns are 
centrifuged for 2 minutes at ≥8000g. The RNeasy columns are placed in a new 2 ml 
collection tube and centrifuged at full speed for 1 min to further dry the membrane. 
Finally, place the RNeasy spin column in a new 1.5 ml Eppendorf tube and add 30µl 
RNase-free water directly to the spin column membrane. This is then centrifuged for 
1 minute at ≥8000g to elute the RNA. 
The concentration (ng/µL) of 1µL collected RNA is then measured using the Nanodrop 
spectrophotometer. The Nanodrop measures absorbance at wavelengths 260nm, 
280nm, and 230nm. These values are then used to determine the purity of the RNA 
eluted via the 260/280 and 260/230 ratios. For pure RNA, the 260/280 ratio should be 
around 2.1; a lower ratio indicates protein contamination. The A260/230 should be 
close to 2.0, with lower than 1.8 indicating significant organic contaminants. 
cDNA synthesis 
The cDNA was prepared using SuperScript™ IV First-Strand Synthesis System 
(Invitrogen). Each sample consisted of 1µg of RNA, 1µL 10mM dNTP mix, 0.5µL 50µM 
Oligio d(T)20 and 0.5µL 50ng/µL random hexamer primers. DEPC-treated water was 
added to make the total volume of each reaction 12µL. These were mixed by pipetting, 
briefly centrifuged, and heated at 65˚C for 5 minutes. The RNA-primer mix is then 
incubated on ice for 1 minute. 
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After, to each RNA-primer mix add the RT reaction mix which consists of 4µL briefly 
vortexed 5x SSIV buffer, and 1µL 100mM DTT, ribonuclease inhibitor, and 
SuperScript™ IV reverse transcriptase. Once mixed and centrifuged, this is heated at 
23°C for 10 minutes, 50°C for 10 minutes, and 80°C for 10 minutes. The prepared 
cDNA was then diluted 1 in 10 with DEPC water, and stored at-20̊C. 
Quantitative real-time (qRT) PCR 
Per reaction, a master mix consisting of the contents of table 2.3 is added to 2.5µL of 
diluted cDNA. 0.1% (v/v) ROX reference dye is added to Syber green mix. Each 




Table 2.3 – Mixture of reagents necessary for one qRT-PCR reaction 
 
qRT-PCR was performed using Mx3005P (Stratagene) according to the 
manufacturer’s instructions. The reaction begins with enzyme activation at 95’C for 15 
minutes, followed with 40 cycles consisting of 95ºC for 15 seconds, 60ºC for 30 
seconds, and 72ºC for 30 seconds. Subsequently after the cycles, the process 
terminates with 95ºC for 1 minute, 58’C for 30 seconds, and 95 ºC for 30 seconds. 
Primers used are in the table 2.4. 
The data was analysed using MxPro which calculates a Ct value for each reaction. 
This is the threshold cycle, the cycle number when the gene product had amplified 
sufficiently to yield a detectable fluorescence signal; a higher Ct value means there is 
less of the gene product. The threshold is set to 0.01. This Ct value is then normalised 
to a reference gene (TBP) Ct value to calculate an average relative expression. The 
standard error of the mean (SEM) is used for the error bars. 
The dissociation curve tab measures fluorescence against temperature for each 
reaction.  Each gene product has a specific melting temperature, so these curves can 
be used to gauge if the reactions are measuring the gene of interest i.e. a specific 
product, or non-specific DNA products.
Volume (µL) Reagent 
7.5 Syber green + ROX 







Forward (5’-3’) Reverse (3’-5’) 
FABP3 TTT AAG TTG GGG GTG GAG TTC ACA AGT GTG GTC TCT TGC CC 
AMHR2 TAC TCA ACC ACA AGG CCC AG GGT CTG CAT CCC AAC AGT CT 
CCBE1 TCA CTG GTG ACA AGG TGC TG CTT CCC TTT GGT CCT GGT G 
FLCN TCT CTC AGG CTG TGG GAG C CCA GCA TGC GGA AAG AAG 
AKR1C1 CCT AAA AGT AAA GCT TTA GAG GCC ACC GAA AAT GAA TAA GGT AGA GGT CAA CAT AAT 
AKR1C2 CCT AAA AGT AAA GCT CTA GAG GCC GT GAA AAT GAA TAA GAT AGA GGT CAA CAT AG 
AKR1C3 CTG ATT GCC CTG CGC TAC TCC TCT GCA GTC AAC TGG AAC 
CLU AGC AGC TGA ACG AGC AGT TT AGC TTC ACG ACC ACC TCA GT 
MYCN CCT CAG TAC CTC CGG AGA GGA TTC TCC ACA GTG ACC ACG TCG 
G9a CAA CTT CCA GAG CGA CCA G GTG AAC AAC CAC CTG GAG GT 
BOK CAA GAC CCT GGC AAC CTG GCT GAC CAC ACA CTT GAG GA 
TBP AGC CAC GAA CCA CGG CAC TGA T TAC ATG AGA GCC ATT ACG TCG T 
ALK CGA CCA TCA TGA CCG ACT ACA A CCC GAA TGA GGG TGA TGT TTT 
CASP8 CAG TCA CTT TGC CAG AGC CT GCA TCT GTT TCC CCA TGT TTT 
 
Table 2.4 – Sequences for primers used in qRT-PCR.
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Preparation of Protein Lysates 
Floating and attached cells were harvested for protein analysis. These were harvested 
by collecting the media from the treated wells and trypsinisation respectively. These 
cells were then pelleted and lysed with 100 to 200 µL RIPA buffer and Inhibitors (1x 
phosphatase (PhoStop™, Sigma Aldrich) and 1x protease inhibitor). These were then 
sonicated (Diagenode Bioruptor) at high frequency in 30 second bursts for two and a 
half minutes. Samples were submerged in ice cold water. If the samples were still 
‘gloopy’, the samples would be re-sonicated. Next, the lysates are centrifuged at 4˚C 
for 15 mins at 13,000 rpm. The protein lysate is now in the supernatant. These samples 
can now be quantified and stored at-80˚C. 
Protein quantification by BCA assay 
Protein concentrations are determined using Bicinchoninic acid assay (BCA) with 
Micro BCA TM protein assay kit (Thermo Fisher). A protein standard curve is made 
using bovine serum albumin (BSA) (2mg/ml) and is added in a range from 0 to 12µL. 
5µL of ddH2O is added to the wells in use and 2µL of protein lysate is then added. 
Each protein lysate is measured in duplicate. 100µL of A, B, C solution (10:9:1 ratio 
respectively) is then added to each well with protein lysate and the plate is incubated 
at 37˚C for 15 minutes. The plate is now read using SpectraMax 190 plate-reader 
(Molecular Devices) at 562 nm. These values can now be compared to the curve to 
determine the volume of lysate necessary for 20µg of protein. 
Immunoblot analysis 
SDS-Polyacrylamide gels were prepared as described in Table 2.5. The samples were 
prepared to contain the same concentration of protein, generally 20µg, 1/5th the total 
volume of 5x SDS loading buffer, with the remainder filled with ddH2O. These samples 
are then heated at 95˚C for five minutes, spun briefly before loading in to the wells of 
the gel. The samples are then run alongside 5µL rainbow ladder protein marker 
(Precision Plus Protein™ Kaleidoscope™) for 1 hour at 160V in 1x Tris-glycine-SDS 
running buffer. 
After the samples have reached the bottom of the gel, the gel is removed from the 
glass cassette, the stacking layer removed, and the gel washed in 1x transfer buffer 
for 5 minutes. At the same time, PVDF membrane (Millipore) is incubated for 5 minutes 
in methanol and then incubated in the tank full of 1x Transfer buffer. 
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To transfer the proteins to the membrane, two sponges and six filter papers were pre-
soaked in 1x transfer buffer.  Within the transfer cassette (Bio-Rad), a sponge, three 
pieces of paper, gel, PVDF membrane, three pieces of paper and sponge was placed 
on top of each other.  This is termed a “sandwich” which at each layer of construction, 
bubbles are carefully pressed out by rolling a stripette across each layer. The protein 
transfer was conducted in the ice-cold 1x transfer buffer at 120 Volts for 1 hour 20 
minutes.  
After transfer, the membrane is now incubated in 5% milk PBST (w/v) for 1 hour whilst 
on a shaker. Next, the membrane is briefly washed with PBST a couple of times before 
being incubated in primary antibody at 4˚C overnight/ 2 hours at room temperature. 
Table 2.6 details all the primary antibodies used. 
After incubation, the membrane is washed three times for four minutes each with 
PBST before being incubated in secondary antibody diluted 1:5000 in 5% milk PBST 
for 1 hour at room temperature on a shaker. After, the membrane is washed four times 
for five minutes in PBST before the protein is detected by chemiluminescence with 
ECL Prime western blotting detection reagent (Amersham Biosciences) (1mL A and B 
per blot). The ECL covers the membrane for five minutes before being placed in an 
autoradiograph cassette and the membranes are then exposed to light-sensitive x-ray 
films (Kodak Diagnostic Film). The exposed films are developed by the Compact X4 
Film Processor (X-ograph Imaging Systems Ltd). 


















Table 2.5 – Ingredients for making the SDS polyacrylamide running and stacking gels. 
 
 
Table 2.6 – List of antibodies used for immunoblotting. 
β-Actin does need a secondary because the primary antibody used is horseradish peroxidase 
(HRP) tagged which emit light.  
 
 
Running Gel RG 10% RG 15% 
ddH2O 7.3 mL 4.4 mL 
Resolving buffer 4.4 mL 4.4 mL 
30% acrylamide/ 1% bis 5.8 mL 8.7 mL 
APS solution 200µL 200µL 
TEMED 6µL 6µL 
Stacking Gel SG 4.5% 
ddH2O 5.9 mL 
Stacking buffer 2.6 mL 
30% acrylamide/ 1% bis 1.5mL 





Dilution Secondary Supplier 
Catalogue 
Number 
G9a 170 1/1000 Rabbit Abcam ab185050 
MYCN 
(B8.48) 
64 1/2000 Mouse Santa Cruz SC-53993 
β-Actin 42 1/40,000 - Sigma A3854 
c-PARP 25 1/1000 Rabbit Abcam ab32064 
BOK 
(D7V2N) 
22 1/500 Rabbit CST 86875 
LC3B 16- 18 1/1000 Rabbit Sigma I7543 
BAK 24 1/500 Mouse BD 55638 
BAX 23 1/1000 Rabbit Santa Cruz SC- 493 
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Transfection of small interfering RNA 
To deplete proteins of interest such as G9a and MYCN, short-interfering RNA (siRNA) 
were used to target these genes. On the day of the transfection, cells would be in their 
exponential growth phase (~60/70% confluent) and media would be replenished a few 
hours beforehand. For each siRNA transfection, two 1.5mL microcentrifuge tubes are 
labelled A and B. To tube A, OptiMem (Invitrogen) and 100µM siRNA are added, and 
to B OptiMem and Lipofectamine RNA iMAX (Invitrogen). The volumes are shown in 
table 2.7. Each tube is vortexed, briefly centrifuged and incubated at room temperature 
for 2 minutes. Then B is added to A and this is vortexed, briefly centrifuged and 
incubated at room temperature for 5 minutes. 100µL is then added slowly to cells that 
haven’t adhered yet. The final concentration of siRNA used was 25nM. The sequences 















Table 2.7 – Volumes of reagents needed for siRNA transfections in 6 well plates and 96 
well plates. The final volume of siRNA is 25nM.  












Tube Reagents Volume (µL) 
A 





RNA iMAX 2 
50 
OptiMem 48 













Tube Reagents Volume (µL) 
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Table 2.8 – siRNA sequences used for transfections. 
 
2.4 – In silico methods 
Kaplan Meier curves 
Using the R2: Genomics Analysis and Visualisation Platform 
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi), the Kaplan Meier curves presented 
were generated under the Kaplan Scanner (overall) side panel for the gene of interest. 
This curve can then be refined by applying set parameter tracks available within the 
datasets used, for example filtering between MYCN status or high risk.  
Semi-quantitative densitometry 
Protein bands detected by immunoblotting were scanned at 600dpi and the 
subsequent semi-quantitative densitometry was performed using ImageJ.  The values 
for the protein of interest were divided by the loading control (β-Actin) to determine a 
ratio which can be used to quantify the amount of protein. 
 
Gene siRNA siRNA sequence (5’-3’) 
G9a siG9a 2 GAA CAU CGA UCG CAA CAU CUU 
G9a siG9a new GAA CAU CGA UCG CAA CAU C 
MYCN siMYCN 1 CCC GGA CGA AGA UGA CUU CUA 
MYCN siMYCN new GAA CCC AGA CCU CGA GUU U 
BOK siBOK#1 CGA GAU CAU GGA CGC CUU U 
Negative control siNEG UGG UUU ACA UGU UUU CUG A 
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2.5 – Buffer recipes 
RIPA Buffer- 
In 200mL ddH2O, add 5mL 1M Tris-HCl (Severn Biotech) (2.5mM), 1.75g Sodium 
Chloride (150mM), 1mL 0.2M ETDA (Severn Biotech) (1mM), 0.4g SDS (0.2% w/v), 
1mL NP40 (0.5% v/v), and 0.4g sodium deoxycholate (0.2% w/v). Adjust to pH 8. Prior 
to protein extraction add 1x Phosphatase inhibitor and 1x protease inhibitor to 10mL 
RIPA Buffer 
 
10x Running buffer- 
In 1L ddH2O, add 30g Tris base, 144g glycine, and 10g SDS 
 
10x Transfer buffer- 
In 1L ddH2O, add 30g Tris base and 144g glycine 
 
1x Transfer buffer- 
100mL 10x Transfer buffer, 200mL Methanol, 700 mL ddH2O 
 
Stripping Buffer- 
In 1L ddH2O, adjust to pH 2.0, add 1.8g glycine and 10g SDS 
 
4x Resolving buffer- 
1.5M Tris-HCl, 0.4% SDS (w/v), pH 8.8 
 
Stacking buffer-  




Ammonium persulphate solution- 
In 1mL ddH2O, add 0.5g APS (50% w/v) 
 
PBST-  
In 1L 1x PBS, add 1000µL (1mL) (0.01% v/v) Tween-20 
 
BSA blocking buffer- 
In 30mL PBST, add (5% w/v) BSA powder and 30µL (0.1% v/v) 10% Sodium Azide 
 
Milk blocking buffer- 
In 50mL PBST, add 2.5g (5% w/v) skim milk powder 
 
MTT- 
50 mg/mL MTT in PBS.  Sonicate and filter. 
 
SDS lysis buffer- 















Assessment of G9a as a 






As discussed in more depth in chapter 1, Histone methyltransferase G9a is suggested 
to be an oncoprotein in various cancers, which is reviewed in depth by Casciello et al 
(116). Yet in the context of neuroblastoma, there is very little published; currently only 
three papers examine the impact of G9a small molecule inhibitor BIX-01294 on cell 
proliferation and cell death (259-261), yet the effect has not been well characterised 
despite the use of similar cell lines.  
Expression of other histone methyltransferases have been suggested to correlate with 
poor prognosis. For example, high expression of histone modifier EZH2 has recently 
been suggested to correlate with both poor prognosis and expression of poor 
prognostic indicator MYCN which helps to repress differentiation in MYCN-amplified 
neuroblastoma (292). Furthermore, arginine methyltransferase PRMT5 expression 
has recently been suggested to correlate with MYCN expression in MYCN-amplified 
neuroblastoma (229). This suggests that MYCN protein can utilise these histone 
methyltransferases to help drive tumour progression, therefore profiling G9a mRNA 
and protein expression between high- and low-risk neuroblastoma based on MYCN-
amplification status may help to elucidate a role between MYCN and G9a, which has 
not been shown before. 
This chapter begins by determining the prognostic potential of high G9a expression in 
neuroblastoma alongside an immunoblot panel of endogenous protein in 
neuroblastoma cell lines to ascertain if there is also a correlation between MYCN and 
G9a protein expression. This chapter also aims to evaluate G9a as an oncoprotein in 
neuroblastoma by assessing the impact of G9a depletion by siRNA transfection on 
cell proliferation and cell death. 
3.2 G9a mRNA expression is increased in poor prognostic and MYCN-amplified 
neuroblastoma 
Neuroblastoma is the most common paediatric solid tumour with evidence to suggest 
the epigenome demonstrates an important role in neuroblastoma tumour proliferation 
(293-295). As mentioned previously, there is plenty of evidence to suggest that G9a 
expression level is associated with poor prognosis in multiple cancer lines, so it stands 
to reason that this epigenetic modifier would likely have a role in neuroblastoma too. 
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However, only one paper has been published in neuroblastoma looking at G9a 
expression and poor prognosis (261). Ke et al were the only group to assess the 
oncogenic potential of G9a by using the Genomic Analysis and Visual Platform R2 
(http://r2.amc.nl), however they only used one dataset, Versteeg-88 (296). Here, they 
showed that increased G9a expression is strongly associated with a poor prognostic 
outcome in neuroblastoma, therefore suggest that G9a can be used as a prognostic 
marker (261).  
In this study, the number of databases was expanded to corroborate these findings of 
G9a as a potential oncoprotein (Figure 3.1). Using three different neuroblastoma 
datasets from the R2 database, including the dataset used by Ke et al, the correlation 
between G9a mRNA expression and survival probability was gauged. The Versteeg- 
88 dataset is a tumour microarray of 88 neuroblastoma tumours, analysis of which 
displayed that tumours with high G9a expression (n=42)  presented a low overall 
survival probability relative to tumours with low G9a (n=46), (Bonferroni p=6.9e-3). 
Comparison of this data with the SEQC-498 dataset, RNA sequencing data from 498 
neuroblastoma tumours, showed a comparable result of high G9a mRNA expression 
(n=62) leading to a significantly decreased overall survival probability (Bonferroni 
p=4.1e-11). Finally, the third dataset, a 44k oligonucleotide array of 649 tumours- 
Kocak-649, again validated this hypothesis that G9a expression correlates with 
survival with high G9a expression (n=131) (Bonferroni p=1.3e-7) (Figure 3.1A). Kocak-
649 lacked survival information for 173 samples so the analysis was only performed 
on 476 tumour samples. The data from these databases all indicate that high G9a 
expression is worse for survival. 
As stated in chapter 1, because MYCN-amplification is a standard marker for high-
risk, poor prognosis neuroblastoma, it seemed logical to determine if G9a expression 
was still a potential poor prognostic indicator in tumours without MYCN-amplification 
similar to lung and bladder cancers (130, 143, 149). This refinement was not 
performed by Ke et al. Using the same datasets as before, the data was refined to 
only use the non-MNA tumours (Figure 3.1B).  The SEQC- 498 and Kocak- 649 
datasets suggested there was still a significant correlation between high G9a 
expression and low survival (Bonferroni p=0.014 and 0.038 respectively). However, 
the correlation suggested by the Versteeg- 88 dataset was not quite significant 
(Bonferroni p= 0.076) despite the Kaplan-Meier suggesting a significant relationship. 
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This was probably due to a reduced sample size relative to the other two datasets 
although the p values were not as low as they were previously. Overall, this data 
suggests that G9a expression is poor prognostic indicator independent of MYCN-
amplification in neuroblastoma. 
Despite two of the three datasets being significant for high G9a mRNA expression in 
non-MYCN-amplified tumours correlating with survival, there was a drastic difference 
in the Bonferroni p value between the datasets in Figure 3.1A and 3.1B. This suggests 
that G9a expression is potentially dictated by MYCN-amplification. Therefore, G9a 
expression was compared between MYCN-amplified and non-MYCN-amplified 
neuroblastoma tumours to examine this relationship in the same three datasets. 
Boxplots produced from the R2 platform using the datasets (Figure 3.2A) shows that 
there is a significant increase in G9a in MYCN-amplified tumours relative to non-
MYCN-amplified tumours (p=3.2e-3, 5.8e-21, 6.1e-18 respectively).  
Moreover, using the SEQC-498 database, the boxplot of G9a expression in MYCN-
amplified vs non-MYCN-amplified was further refined to only use high-risk tumours 
(Figure 3.2B). This suggested a significant increase in G9a expression in the high-risk 
MYCN-amplified relative to high-risk non-MYCN-amplified suggesting G9a is a viable 
risk factor and a potential therapeutic marker for poor prognosis. The other two 
databases did not have a risk factor filter which is why this analysis was only performed 
in the SEQC-498 database. 
Because of the correlation at the RNA level, it was necessary to determine if this was 
true at the protein level too. A panel of protein lysates from five MYCN-amplified, three 
non-MYCN-amplified neuroblastoma, and two disease-free cell lines were 
immunoblotted for G9a and MYCN (Figure 3.2C). β-actin was used a loading control 
and MYCN protein was overexpressed in all the MYCN-amplified cell lines. There was 
higher expression of G9a protein the MYCN-amplified cell lines relative to the non-
MYCN-amplified. This relationship was quantified using semi-quantitative 
densitometry of the immunoblots using image J (Figure 3.2D). Relative G9a was 
quantified to β-actin. Relative G9a levels were shown to be significantly higher in the 
MYCN-amplified cell lines relative to non-MYCN-amplified and disease-free cell lines 
(*** p<0.001). G9a was ubiquitously expressed in all the cell lines tested, however at 
lower levels in the non-MNA and disease-free. In addition, there are two bands shown 
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for G9a, the top is isoform A and the bottom is the shorter isoform B. The immunoblot 
suggests that there is generally more of A than B, yet there is no pattern in the amount 
of B between the cell lines. 
Overall, examination of G9a and MYCN mRNA and protein in neuroblastoma cell lines 
strongly suggests that G9a is more highly expressed in MYCN-amplified cells. 
3.3 G9a depletion in Kelly cells has a significant effect on cell growth 
High G9a mRNA and protein expression in MYCN-amplified cell lines strongly 
suggests G9a has a role as a potential oncoprotein. Therefore, to assess the functional 
role of G9a in neuroblastoma, MYCN-amplified Kelly cells were transfected with two 
short interfering RNAs (siRNAs) targeting G9a histone methyltransferase. 
Phenotypically, there was a significant difference between the non-target control and 
the two G9a depleted cells with there being drastically less cells in the treatments 
(Figure 3.3A) suggesting cell proliferation repression along with more detached and 
floating cells which is indicative of cell death. Furthermore, they were phenotypically 
distinct with the siG9a treated cells looking more rounded morphologically and dead, 
again suggesting cell death. The phenotypic effect of G9a depletion in neuroblastoma 
cells has not been published to date. 
The floating and attached cells were harvested and immunoblotted for G9a to confirm 
the G9a knockdowns (Figure 3.3B). In addition, the presence of apoptotic cell death 
was suggested by the increase in cPARP in both siG9a treatments (Figure 3.3B). 
Since the phenotypic and cPARP changes are similar between the two transfections 
relative to the negative control, it can be safely assumed that this is not an off-target 
effect of the siRNA transfection. 
The cells were monitored by live cell imaging system IncuCyte Zoom for percentage 
phase confluence to assess the phenotypic effects of G9a depletion. G9a depletion in 
Kelly cells resulted in a significant decrease (n=3, * p<0.05) in percentage phase 
object confluence relative to the non-target control siNEG from 36 hours with siG9a2 




Figure 3.1 – High G9a mRNA expression correlates with poor prognosis in 
neuroblastoma 
A – Kaplan-Meier survival curves of neuroblastoma show a positive relationship between high 
G9a mRNA expression and poor prognosis. The blue and red lines represent high and low 
G9a mRNA expression respectively, whilst n represents the number of tumours in each 
category. This correlation was shown in three separate named tumour array datasets. 
Versteeg-88 analysis derives from microarray data analysing eighty eight human tumours 
(297). SEQC-498 is derived from RNA sequencing data of 498 neuroblastoma. Kocak-649 is 
generated using 44K oligonucleotide microarrays of neuroblastoma tumours and cell lines 
(298). In the Kocak-649 dataset, only 476 of the 649 neuroblastoma samples were analysed 
as only these had survival information available (222). B – Kaplan-Meier survival curve from 
the databases shown in A were refined to only include tumours with non MNA states. This 
showed that there is a positive relationship between high G9a mRNA expression and poor 
prognosis after poor prognostic indicator MYCN-amplification is taken out. The blue and red 
lines represent high and low G9a mRNA expression respectively, whilst n represents the 




Figure 3.2 – High G9a protein expression correlates with MYCN protein 
A – Significantly higher G9a mRNA expression is observed in MNA neuroblastoma relative to 
non MNA. This correlation was shown in three separate named tumour array datasets 
previously mentioned in Figure 3.1. The red and green colours represent MNA and non MNA 
respectively, with the bracketed numbers representing the number of tumours. The p-values 
are calculated by one-way ANOVA (Analysis of Variance) on R2. B – Significantly higher G9a 
mRNA expression is observed in MNA neuroblastoma relative to non MNA in high-risk only 
neuroblastoma tumours. This filter was added in the SEQC- 498 database. C – Immunoblot 
of G9a protein expression in a panel of MYCN- and non-MYCN-amplified neuroblastoma cell 
lines. β-Actin is used as a loading control. Representative of two biological replicates. D – G9a 
expression is higher in MNA neuroblastoma when normalised to β-Actin. Box plot of relative 
G9a protein is generated from semi-quantitative densitometry of blots from C. G9a expression 






Figure 3.3 – G9a influences proliferation and survival in Kelly cells 
A – Photomicrographs at 10x objective magnification of Kelly cells after 72-hour knockdown 
of histone methyltransferase G9a via siRNA transfections. B – Graph depicting the percentage 
phase object confluence of the siG9a transfected Kelly cells relative to the negative control, 
siNEG. The asterisk and lines below the graph mark significant changes in phase object 
confluence for each G9a siRNA treatment relative to the negative control (n=3, * p<0.05). Error 
bars show the SEM. C – Immunoblot confirming the knockdowns from samples shown in A. 
These are the negative control, siNEG, and two different G9a siRNAs. cPARP is indicative of 
cell death. β-Actin was used as a loading control. 
 
3.4 G9a depletion leads to apoptotic cell death 
The Kelly cells depleted of G9a in Figure 3.3 were phenotypically distinct relative to 
the negative control as they were rounded and there was a high quantity of floating 
cells indicative of apoptosis and cell death as well as an increase in cPARP relative to 
the negative control. This is all indicative of apoptotic cell death so to confirm this, a 
pan-caspase inhibitor, Q-VD-OPh (QVD), was added to G9a depleted Kelly cells in a 
96-well format. These cells were also monitored by live cell imaging system IncuCyte 
Zoom for percentage phase confluence. A significant and similar decrease in phase 
object confluence was seen in the treatments with and without QVD after 28 hours 
(p<0.05) suggesting this decrease in proliferation is not due to apoptosis (Figure 3.4A). 
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The IncuCyte also measures red object count; visible cell death was present alongside 
the reduced proliferation, so DRAQ7, a red-fluorescence non-permeable DNA dye, 
was added to quantify the change in dead cells. The normalised object red count 
(Figure 3.4A) reveals that there is an increase in the volume of dead cells detected, 
significantly so after 44 hours, as shown by the green line, p<0.05. Apoptosis was then 
rescued by the addition of QVD as shown by the red object count for both siNEG and 
siG9a transfections being similar. They were both indifferent from their starting 
normalised red object count suggesting successful ablation of apoptosis. This 
inhibition was significantly different to QVD negative treatments after 22 hours, as 
shown by the black line, p<0.05.  
Phenotypically, there were less floating and rounded cells observed in the siG9a 
treatments with the addition of QVD (Figure 3.4B), suggesting that the apoptosis is 
rescuable. However, the cells did not match the siNEG treatment with QVD further 
emphasising that G9a influences other cell process like proliferation. 
When scaled up to a 12-well format, cells of the same treatment were harvested, and 
trypan blue inclusion assay performed to count the dead cells. There is an expected 
increase in cell death in the G9a depleted cells relative to the negative control in the 
QVD-negative treatments, over 1.5-fold increase (n=2, * p<0.05) (Figure 3.4C). 
Furthermore, in the presence of QVD, G9a depleted cells were rescued from cell death 
with over a 2-fold decrease in percentage cell death relative to the QVD negative 
control (n=2, * p<0.05). However, there was no significant difference in the level of 
basal death between the QVD positive and negative treatments despite a significant 
difference in the red object count data. This suggests that there may be a difference 
in basal cell death dependent on the total number of cells in a well at one time. 
An immunoblot of the floating and adherent cell lysates (Figure 3.4D), not only 
confirmed an effective knockdown of G9a protein, but also there is no change in 
cPARP levels in the treatments with QVD added relative to the significant increase in 
cPARP with siG9a added and previously seen in Figure 3.3B. This is a further 
suggestion that this cell death is apoptotic. 
All this data suggests that the death observed in G9a-depleted Kelly cells occurs 
through caspase-dependent apoptosis, which agrees with the conclusions drawn by 
Lu et al (260). 
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3.5 Apoptotic cell death associated with G9a depletion is preferential to MYCN-
amplified neuroblastoma 
Since G9a and MYCN mRNA and protein expression correlate, the effect on cell death 
and proliferation by depleting G9a in non MNA amplified cell lines needed to be 
examined to determine if this is an artefact of the MYCN status of neuroblastoma. 
G9a was depleted in non MNA neuroblastoma cell lines Gimen. Using the trypan blue 
inclusion assay as mentioned previously with the Kelly cells, the live and dead cell 
counts were measured in Gimen cells treated with siRNA G9a new (here after denoted 
as siG9a) after 72 hours. There was no significant increase in the percentage cell 
death seen in the G9a depleted cells relative to the negative control (n=4, p=0.23) 
suggesting that G9a depletion has no death response in Gimen cells (Figure 3.5A). 
However, there was still a very significant decrease (n=4, *** p<0.01) in the number of 
live cells in the treated cells relative to the negative control. This can be used to 
assume that the growth rate inhibition effect exhibited by G9a depletion is still present 
despite the lack of apoptotic cell death in Figure 3.5A. This is further shown by 
immunoblotting the protein lysates from the treated cells (Figure 3.5B). An effective 
knockdown was confirmed, yet there was no increase in apoptosis indicator cPARP. 
Other non-MYCN-amplified cells, SKNAS and SHSY5Y, were also depleted of G9a. 
The same lack of change in cPARP levels as seen in the Gimen cell line was also 
observed (Figure 3.6) despite effective G9a depletion suggesting that this apoptosis 
only occurs in MYCN-amplified cell lines.  
Overall, this data suggests whilst G9a depletion seemingly has a universal effect on 
the inhibition of cell growth, whereas apoptotic death that is driven by the depletion of 
G9a in neuroblastoma is dependent on the MYCN-amplification status of the 
neuroblastoma as apoptosis is only observed in the MNA cell lines Kelly, LAN-1, and 





Figure 3.4 – Depletion of G9a leads to apoptosis. This can be rescued by the addition 
of apoptosis inhibitor QVD 
A – Graph depicts the normalised percentage phase object confluence as a proxy of cell 
growth. The cells were transfected with siRNA at 25nM and incubated for 72 hours. QVD was 
added at a concentration of 10µM. This shows that the decrease in cell growth associated with 
G9a depletion was not affected by QVD. The blackline underneath the graph shows 
significance (*** p<0.01) after 28 hours. Normalised red object counts shows that G9a 
depletion leads to apoptotic cell death due to a significant increase in the red object count, a 
proxy for cell death, after 44 hours (* p<0.05, n=2, green line) between siNEG and siG9a new. 
Also, the effect of apoptosis inhibitor QVD is significantly apparent after 22 hours (* p<0.05, 
n=2, black line) showing that the apoptosis is rescuable. Error bars show the SEM. B – 
Photomicrographs at 10x objective magnification of the treatments from A. These show the 
phenotype of apoptotic phenotype along with the rescuable apoptosis. C – Floating and 
adherent cells from A were harvested and counted for trypan blue inclusion assay. The graph 
depicts the percentage cell death of G9a depletion relative to the negative control, with and 
without QVD. The asterisks mark significant changes (p<0.01, n=2). There is a significant 
increase in cell death because of G9a depletion relative to the negative control, and the effect 
of QVD is further apparent due to the significant reduction in cell death caused by siG9a new 
with QVD relative to the negative control with QVD. Error bars show the SEM. D – Immunoblot 





Figure 3.5 – Apoptotic cell death caused by G9a depletion does not occur in Gimen 
cells 
A – Floating and adherent cells from Gimen cells treated with negative control, siNEG, and 
siG9a new were harvested and counted by trypan blue inclusion assay. The left-hand graph 
shows the percentage cell death between the two treatments. The righthand graph shows the 
live cell count (105) of the Gimen cells harvested in A. The live cell count is used as a gauge 
for cell growth. Significant changes are measured the asterisks (*** p<0.01, n=4). Error bars 
show the SEM. B – Immunoblot of the treatments from A and of SKNAS and SHSY5Y cells 
transfected with negative control, siNEG, and siG9a new. It confirms the knockdowns of G9a, 
and that no apoptosis is occurring as shown by cPARP Cleaved PARP (cPARP) is indicative 
of apoptosis. β-Actin is used as loading control.  
 
 
Figure 3.6 – Apoptotic cell death caused by G9a depletion does not occur in SKNAS or 
SHSY5Y cells 
Immunoblot of floating and adherent cells from SKNAS and SHSY5Y cells treated with 
negative control siNEG and siG9a. cPARP is a marker for apoptosis and cell death. β-Actin is 





To ascertain if apoptosis truly is dependent on the MYCN-amplification of the 
neuroblastoma, therefore G9a and MYCN are potentially synthetic lethal, G9a was 
depleted in SHEP-21N (S21N) cells. S21N cells are engineered from non-MNA SH-
EP and contain a system that allows for the expression of MYCN in the absence of 
tetracycline (TET) (299). This enables the effect of G9a depletion to be determined in 
two cell lines that only differ in their MYCN-amplification state determining if this is a 
MYCN-amplified neuroblastoma trait. 
G9a depleted S21N cells with and without TET were harvested and trypan blue 
inclusion assay was performed to determine if the G9a depletion-associated apoptosis 
is directly determined by the MYCN-amplification state of neuroblastoma (Figure 
3.7A). In the S21N with TET (MYCN expression off), there was no difference in the 
percentage cell death between the negative control and the cells depleted of G9a. 
However, in the S21N without TET (MYCN expression on), there is a very significant 
increase in cell death (n=3, *** p<0.01,) between the two treatments. This apoptotic 
cell death was confirmed by immunoblotting the treated cells for cPARP (Figure 3.7B). 
There was no change in cPARP between the MYCN off S21N cells yet there was an 
increase in the cPARP levels in the MYCN on S21N cells further solidifying that G9a 
depletion-induced apoptosis MYCN dependent. 
Moreover, in S21N cells with MYCN on, MYCN protein completely disappeared when 
G9a was depleted (Figure 3.7B). The extent of MYCN protein depletion is surprising 
as this link between G9a inhibition and MYCN has only been suggested once (260); 
the effect on MYCN protein after G9a depletion has not been shown before. This adds 
further evidence to G9a and MYCN being positively linked.  
64 
 
Figure 3.7 – G9a knockdown preferentially kills MYCN-amplified neuroblastoma cells 
A – The graph shows the percentage cell death of S21N cells in the presence and absence 
of tetracycline to alter their MYCN expression. These cells were transfected with siG9a new 
to deplete G9a and cell death was measured 72 hours later after trypan blue inclusion assay. 
There is no difference in cell death in the S21N with tetracycline (MYCN OFF) but a significant 
increase in those without tetracycline (MYCN ON) (*** p<0.01, n=3). Error bars show the SEM. 
B – Immunoblot of cell lysates from A. This confirms the increase in cPARP protein because 
of G9a depletion only in the MYCN-amplified S21N cells. β-Actin is used as the loading control. 
    
3.6 Discussion 
The aim of this chapter was to assess G9a as a potential oncoprotein in neuroblastoma 
by expression and function analysis; the results suggest that G9a expression 
correlates with MYCN-amplification. Depletion of G9a exhibits a profound inhibition in 
proliferation in tested neuroblastoma cell lines; this is not cell death dependent. 
Furthermore, effective G9a depletion in tested MYCN-amplified cell lines leads to an 
increase in apoptotic cell death which is not exhibited in tested non-MYCN-amplified 
cell lines suggesting a potential synthetic lethal relationship between G9a and MYCN. 
In both MYCN- and non-MYCN-amplified neuroblastoma cell lines with G9a depleted, 
there is a significant decrease in the proliferation. Real-time phase object confluence 
data recorded by the IncuCyte showed a significant plateauing of cell growth in MYCN-
amplified Kelly cells from 24-to-36 hours after successful siRNA transfection over a 
72-hour time course. Furthermore, Gimen cells with wild type G9a had a significantly 
greater number of live cells, a proxy for proliferation rate, relative to those cells with 
G9a depleted after 72-hour knockdowns. This is similar to results shown in gastric 
carcinoma cells MGC-803 with G9a depletion leading to decreased cell proliferation 
(147). These cells are also non-MYCN-amplified as MYCN is not a risk factor in gastric 
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carcinoma. This all suggests that G9a is an oncogene involved in cell proliferation in 
neuroblastoma independent of high-risk factor MYCN. 
Depletion of G9a was also shown to induce apoptosis in MYCN-amplified 
neuroblastoma cell lines tested suggesting a potential synthetic lethal relationship. 
Depletion of G9a in Kelly cells led to a consistent increase in apoptosis indicator 
cPARP. This was not seen in the three non-MYCN-amplified neuroblastoma Gimen, 
SHSY5Y, and SKNAS when G9a was depleted. G9a knockdown in MYCN-inducible 
S21N cells further suggests this synthetic lethal relationship as apoptosis following 
G9a depletion is dependent on the presence of MYCN. This link is also addressed in 
the next chapter when the current small molecule inhibitors of G9a are assessed in 
multiple cell lines. G9a depletion-associated apoptosis has been suggested in other 
cancers such as gastric carcinoma (147), colorectal cancer (154), non-small-cell lung 
cancer (300), and osteosarcoma cancer cells (301). These are not MYCN-amplified 
cell lines however, which suggests a novel relationship between MYCN and G9a in 
MYCN-amplified neuroblastoma cell lines.  The data presented in this chapter 
suggests a role for G9a in repressing apoptosis in neuroblastoma. There is an 
increase in apoptosis following G9a depletion which is rescued following use of potent 
pan-caspase inhibitor QVD. This shows that this apoptosis is caspase-dependent.  
This synthetic lethal relationship has not been tested before in studies regarding 
neuroblastoma as apoptotic cell death has only been suggested by Lu et al. Here they 
treated MYCN-amplified LA1-55n cells with by small molecule inhibitor BIX-01294 and 
evaluated the effect on caspase 3 and caspase 8 activities (260). Therefore, although 
BIX-01294 mediated G9a inhibition has been shown in both MYCN states, a 
comparison between the two, and subsequent suggestion of a lack of apoptosis in the 
non-MYCN-amplified, has not been shown before. 
An unexpected result from this chapter was the complete downregulation of MYCN 
protein in the S21N cells with MYCN ON after G9a depletion (Figure 3.6 B). G9a and 
MYCN regulation has only been shown once and very fleetingly in published literature. 
Lu et al suggests that LA1-55n cells treated with 5µg/ml (8.33µM) BIX-01294 for 24 
and 48 hours show a significant change in MYCN mRNA expression. Moreover, LA1-
55n cells were treated with 1, 2.5, and 5µg/ml (1.67, 4.17, and 8.33 µM respectively) 
for 24 hours show a reduction in MYCN protein in a dose dependent manner (260). 
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There are many issues with these results however. As mentioned previously, BIX-
01294 has been shown to toxic above concentrations of 4.1µM (166), therefore the 
results from treatments using concentrations ≥2.5µg/ml are most likely an artefact of 
off-target toxicity. Therefore, the only reliable result shown is the immunoblot of MYCN 
protein change after 1µg/ml which is not significant.  
They also do not show if MYCN decrease is mirrored in G9a depleted cells which is 
why this was assessed first. Furthermore, in the MYCN protein immunoblot, β-actin 
control looks as if it decreases alongside the MYCN suggesting that this could be a 
reason for the MYCN decrease. Therefore, there are issues with the result described 
by Lu et al which are addressed in the data shown in this chapter. 
MYCN has been shown to be regulated by other epigenetic and post-translational 
modifiers such as PRMT5 (229) and Aurora kinase A (253), therefore G9a could also 
directly methylate MYCN like it does other non-histone targets or indirectly via a 
complex, which may lead to a destabilisation effect at the protein level which may 
suggest why the G9a depletion in the MYCN induced S21N cells led to MYCN 
depletion. The relationship between G9a and MYCN is further explored in Chapter 5 
when G9a inhibition and MYCN protein and mRNA expression are evaluated in more 
detail. 
To conclude, this chapter suggests that G9a is an oncogene in neuroblastoma, and is 
primarily involved in driving cell proliferation, but with the assistance of MYCN-
amplification, G9a can also act as a survival factor to inhibit apoptotic cell death, thus 
share a synthetic lethal relationship. This chapter is also the first instance of a synthetic 
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As shown in chapter 3, G9a is an oncoprotein in neuroblastoma whose depletion leads 
to decreased cell proliferation and an increase in apoptotic cell death suggesting G9a 
acts as a key survival factor. This suggests that G9a represents an important target 
for novel therapeutics, especially in high-risk poor prognostic MYCN-amplified 
neuroblastoma, therefore the need to determine the efficacy of current small molecule 
inhibitors specific to G9a is paramount. None of the G9a and neuroblastoma papers 
mentioned in chapter 1 assessed the effect of MYCN-amplification on G9a inhibition as the 
cell lines used were not categorised in to MYCN-amplified and non-MYCN amplified. It 
therefore seemed that this should be assessed in this chapter given the results thus far relating 
to MYCN-amplification and apoptotic cell death. 
Most studies using G9a small molecule inhibitors utilise BIX-01294 despite it being the 
eldest generation G9a small molecule inhibitor available (75), which is most likely 
because of the potency. As mentioned previously BIX-01294 has been suggested to 
be toxic at concentrations above 4.1µM, therefore these studies are potentially 
unreliable. For example, Woo et al has recently suggested that BIX-01294 sensitises 
renal cancer cells to TRAIL-induced apoptosis (302), however the concentrations of 
BIX-01294 Woo et al use is above this 4.1µM threshold (10µM) suggesting this 
sensitising effect seen may actually be an effect of off-target toxicity. 
To date there has been no study comparing small molecule G9a inhibitors, mentioned 
in chapter 1, to test their effectiveness in reducing cell viability in any cell line, let alone 
neuroblastoma. The previous chapter of this thesis demonstrated G9a as an 
oncoprotein in neuroblastoma and that depletion of G9a in MYCN-amplified 
neuroblastoma triggered caspase-dependent apoptotic cell death to occur. This 
highlights the potential for G9a inhibition as a therapeutic strategy in poor prognostic 
high-risk neuroblastoma. In this chapter, the aim is to evaluate the sensitivity of 
neuroblastoma cell lines to G9a small molecule inhibitors. 
4.2 Assessing the potency of G9a small molecule inhibitors Kelly 
neuroblastoma cells 
The small molecule inhibitors available at the start of this project were UNC0638, 
UNC0642, UNC0646, and A366. The potency of these compounds was evaluated in 
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this section for their potential as therapeutic agents for neuroblastoma, specifically 
looking at the efficacy in high-risk MYCN-overexpressing neuroblastoma. 
The four compounds were tested by MTT based cell proliferation assay to determine 
the potency of these inhibitors in Kelly neuroblastoma cell line (Figure 4.1A). The 
potency was measured by determining an IC50 for each compound, the concentration 
of a drug required for 50% inhibition in vitro. UNC0638 and UNC0642 were more 
potent (p<0.05, n=3) than the other inhibitors as they were the only inhibitors to have 
an IC50 below 10µM. All the inhibitors exhibited a similar response up to 1.25µM, but 
Kelly cells are more sensitive to small molecule inhibitors UNC0638 and UNC0642 
from 2.5µM onwards. There was over a two-fold difference between the IC50 values of 
UNC0638 and UNC0642, with UNC0638 having a very significantly lower IC50 (p<0.01, 
n=3), and the same difference again between UNC0642 and UNC0646. A366 did not 
register an IC50 at the highest tested concentration of 20 µM (Figure 4.1B). 
Therefore, the two inhibitors UNC0638 and UNC0642 would be candidates for a small 
molecule inhibition screen on a wider panel of neuroblastoma and disease-free cell 
lines. 
 
Figure 4.1 – Compounds UNC0638 and UNC0642 are more effective at reducing cell 
viability in Kelly cells after 72 hours 
A – Neuroblastoma Kelly were screened by MTT based cell proliferation assay to determine 
sensitivity to small molecule inhibitors A366, UNC0638, UNC0642, and UNC0646. These 
were treated in a serial dilution from 20 µM for 72 hours, n=3. 0.1µM is the labelled proxy for 
0µM due to the log scale on the x-axis. Error bars show the SEM. B – Table of MTT assay 
based IC50 (µM) values determined for the Kelly treatments from A. Values are means ± 




                                                                                                                                                                                                                                                                               
4.3 G9a small molecule inhibitors preferentially inhibits cell growth in MYCN-
amplified neuroblastoma cell lines 
Having previously demonstrated the activity of UNC0638 and UNC0642 in Kelly cells, 
these small molecule inhibitors were next tested in a wider panel of neuroblastoma 
cell lines. Eight neuroblastoma cell lines- five MYCN-amplified and three non-MYCN-
amplified and two disease-free cell lines, RPE-1 and NF-TERT, were tested and their 
respective IC50’s assessed similar to that described by Kollareddy et al (303). 
Therefore, the efficacy of UNC0638 and UNC0642 modulated inhibition needed to be 
established by determining the IC50 values.  
All the neuroblastoma cell lines tested had a reduced viability upon treatment with 
UNC0638 (Figure 4.2A) and UNC0642 (Figure 4.2B). The small molecule inhibitors 
had no apparent effect on the disease-free cell lines with a percentage survival of 
roughly 100% at the highest concentration tested suggesting the drugs would not harm 
non-cancerous cells.  
There was also an obvious genotype segregation attributable to MYCN-amplification 
as the five MYCN-amplified neuroblastoma cell lines (Kelly, NGP, LAN-1, BE(2)C, 
IMR32) were significantly more sensitive than the three non-MYCN-amplified 
(SHSY5Y, SKNAS, Gimen) when treated with UNC0638 (p=0.0028), and UNC0642 
(p=0.0006). The disease-free cell lines were not added to this analysis. This is 
emphasised by graphs that show the average percentage survival based on all MNA 
and non-MNA cell lines treated with UNC0638 and UNC0642 inhibitors (Figure 4.2C 
and D). A clear trend is shown that MNA cell lines are more sensitive to G9a small 
molecule inhibitors than non-MNA.  
The IC50’s ranged from 2.8 to 16.5µM in the MNA cell lines treated with UNC0638 and 
5.9 to 19.7µM with UNC0642 (Figure 4.2E). The non-MNA were all consistently over 
20µM. The IC50 values are visualised (Figure 4.2F), with a suggested significant trend 
towards MYCN-amplification and a sensitivity towards G9a inhibition. Furthermore, 
this chart suggests that in UNC0642, there is a greater difference in the concentration 
of drug required to illicit an IC50 value between the two genotypes. Although only three 
non-MYCN-amplified cell lines were tested, this data highlights the exciting efficacy 





Figure 4.2 – Small molecular inhibitors UNC0638 and UNC0642 inhibition of 
neuroblastoma cells 
A – Eight neuroblastoma cell lines, five MYCN-amplified (red lines), three non-MYCN-
amplified and two non-cancerous cell lines (black) were screened by MTT based cell 
proliferation assay to determine sensitivity to G9a inhibitors UNC0638 and 0.1 µM is a proxy 
for 0 µM due to the log scale on the x axis. MYCN-amplified neuroblastoma cell lines are more 
sensitive than the non-MYCN-amplified. Error bars show SEM. B – Same as A but using small 
molecule inhibitor UNC0642. C and D – Average values for all of the MNA and non-MNA cell 
line treatments from A and B. UNC0638 (C) and UNC0642 (D). Error bars show SEM. E – 
Table of MTT assay based IC50  (µM) values determined for the cell lines from A and B. Values 
are means ± SEM of three independent experiments. (IC50 (µM): Half maximal inhibitory 
concentration). Red colour is indicating MYCN-amplification. F – MTT assay based IC50 (µM) 
values for UNC0638 and UNC0642 from A and B are visualised as a scatter graph between 
MYCN- (MNA) and non-MYCN- amplified (Non- MNA) cell lines. Error bars show the SEM.  
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4.4 MYCN-amplified S21N neuroblastoma is more sensitive to UNC0638 G9a 
small molecule inhibitor 
Next, these drugs were evaluated in SHEP-21N cells to further assess the effect 
MYCN has on G9a small molecule inhibitor sensitivity.  
The cells with the active MYCN state, MYCN ON, were significantly more sensitive to 
both UNC0638 and UNC0642 (p<0.01, n=3) than the MYCN OFF SHEP-21N cells 
(Figure 4.3A-B). The IC50 values for MYCN OFF (29.6µM and 34.8µM) were over 2.5-
fold more than those for MYCN ON (8.9µM and 13.2µM) for UNC0638 AND UNC0642 
respectively (Figure 4.3C). 
This further supports that small molecule inhibitors of oncoprotein G9a has a 
therapeutic use in high-risk MYCN-amplified neuroblastoma because of a synthetic 
lethal relationship between G9a and MYCN. 
 
 
Figure 4.3 – Small molecular inhibitors UNC0638 and UNC0642 inhibits cell growth 
preferentially in MYCN-amplified neuroblastoma cells 
A – Screening of MYCN-inducible cell line S21N with and without tetracycline using drug 
UNC0638. MYCN-amplified (MYCN ON) cell lines (red) are more sensitive than non-MYCN-
amplified (MYCN OFF) cell lines (black). All MTT assays were carried out in three independent 
biological replicates each having three technical replicates (n=3, mean ± SEM) 0.1 µM is a 
proxy for 0 µM due to the log scale on the x axis. Error bars show the SEM.  B – Screening of 
MYCN-inducible cell line S21N with and without tetracycline using drug UNC0642. Error bars 
show the SEM. C – Table showing the MTT assay based IC50 (µM) values for MYCN-amplified 
and non-MYCN-amplified S21N neuroblastoma. This is determined using an average of the 
IC50 (µM) values from three biological repeats. 
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4.5 UNC0638 effectively represses proliferation in neuroblastoma  
Since there is no plan to do in vivo work, UNC0638 was selected for further study as 
it was more potent than its UNC0642 counterpart so the poor PK properties of 
UNC0638 will not hinder this study. 
To ascertain if the effects of G9a inhibition are akin to the proliferation repression seen 
from G9a depletion in neuroblastoma in chapter 3, neuroblastoma cells were treated 
with UNC0638 over 66 hours. Kelly cells were initially treated as these were the most 
sensitive cell line in the UNC0638 treatment screening (Figure 4.2C). Kelly cells were 
treated with one and two times the IC50 value discovered for UNC0638, 2.5µM and 
5µM respectively. 
Phenotypically, the treated Kelly cells look akin to the G9a depleted cells with more 
rounded and dead cells (Figure 4.4A). This appears to be concentration dependent as 
there are more dead cells at the higher concentration. Moreover, there are less cells 
in the two treated cells relative to the DMSO control suggesting a reduction in cell 
proliferation as observed previously. This is confirmed by the live cell imaging system 
IncuCyte Zoom which measured the percentage phase confluence of these cells 
(Figure 4.4B). This shows a significant reduction in the normalised phase confluence 
in the two treated cell lines in a dose dependent manner, with 2.5 µM significantly 
(*p≤0.05) different after 32 hours, and 5 µM significantly (*p≤0.05) and very 
significantly (***p≤0.01) different from 14 hours and 24 hours respectively. MYCN-
amplified IMR32 cells were also treated with 5µM UNC0638 for 72 hours, to see if this 
effect was seen in other MYCN-amplified cell lines. These cells also reduced in 
proliferation with less cells seen phenotypically (Figure 4.5A). Again, they are also 
more rounded indicative of cell death as well as the neurites being shorter and less 
defined. In addition, the normalised phase confluence graph confirms a very significant 




Figure 4.4 – G9a inhibitor UNC0638 inhibits proliferation in Kelly 
A – Photomicrographs at 10x objective magnification of Kelly cells after 66-hour treatment with 
negative control DMSO, 2.5µM, and 5µM G9a small molecule inhibitor UNC0638. B – Graph 
depicting normalised phase object confluence of the UNC0638 treated Kelly cells from A, 
relative to the DMSO control. Significance was evaluated at each time point by using  T tests, 





As G9a knockdowns in tested non-MYCN-amplified cell lines suggested a decrease 
in cell proliferation, Gimen and SHSY5Y cells were treated with 10µM UNC0638 for 
72 hours to assess if this still occurred. When the Gimen treatments were harvested, 
trypan blue inclusion assay was performed to count the live cells. This live cell count 
was used as a proxy for cell proliferation as if there were more cells it would suggest 
that they are proliferating at a greater rate. The Gimen cells showed a significant 
reduction (* p<0.05, n=2) in live cell count after UNC0638 treatment, with over a 1.5-




Figure 4.5 – G9a inhibitor UNC0638 inhibits proliferation in IMR32 cells 
A – Photomicrographs at 10x objective magnification of IMR32 cells after 72-hour treatment 
with negative control DMSO and 5µM G9a small molecule inhibitor UNC0638. B – Graph 
depicting normalised phase object confluence of the UNC0638 treated IMR32 cells from A, 
relative to the DMSO control. Significance was evaluated at each time point by using T tests 
*** (p<0.01). Error bars show the SEM. 
Figure 4.6 – UNC0638 inhibits proliferation in Gimen and SHSY5Y cells 
A – Floating and adherent cells from Gimen cells treated with negative control, DMSO and 
10µM UNC0638 were harvested and counted by trypan blue inclusion assay. The number of 
live cells were then counted. This is used as a proxy for cell growth at the 72-hour end point. 
Significant changes are indicated by asterisks (* p<0.05, n=2). B – SHSY5Y treated cells were 
measured for percentage phase object confluence in the live cell imaging system IncuCyte 
Zoom at the 72-hour end point. Significant changes are indicated by asterisks (*** p<0.01, 
n=3). Error bars show the SEM.        
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SHSY5Y cells were recorded by the IncuCyte Zoom after the 72-hour treatment to get 
a snapshot of the percent phase object confluence at the 72-hour end point. Again, 
this is used as a proxy for cell proliferation. There was over a third difference in the 
reduction in percentage phase object confluence after treatment, which was very 
significant (*** p<0.01, n=3) (Figure 4.6B). The percentage cell death from these 
trypan blue inclusion assays are shown further on in Figure 4.8.  
All together this suggests that G9a inhibition by small molecule inhibitor UNC0638 
elicits a reduction in cell proliferation in both genotypes of MYCN-amplified 
neuroblastoma cell lines, similar to that seen with G9a depletion. 
4.6 UNC0638 induces apoptosis in MYCN-amplified neuroblastoma 
As there was apoptosis in only the MYCN-amplified neuroblastoma cell lines depleted 
of G9a, and since there is a similar effect on proliferation reduction between G9a 
depletion and UNC0638 small molecule inhibition, it is necessary to determine if this 
is also the case with cell death. An extensive cell panel assessing potential apoptotic 
cell death from G9a small molecule inhibitors has not been performed before. 
UNC0638 was added to eight neuroblastoma cell lines to evaluate the apoptosis 
inducing potential of G9a inhibition. 
Since the photomicrographs from figure 4.4 A and C showed an increase in rounded 
and floating cells indicative of cell death in the treated cells relative to the DMSO 
control, DRAQ7 was added to Kelly from figure 4.4 A and SKNAS treatments to 
visualise and quantify the amount of cell death. 
In the Kelly cells treated with 2.5µM UNC0638, over the 66-hour treatment, there was 
an increase in the normalised red object count relative to the DMSO control. This was 
significant (p<0.05, n=3) from 18 hours after treatment was added and very significant 
(p<0.005, n=3) from 24 to 58 hours (Figure 4.7A). The reduction in significance during 
the final eight hours can be attributed to the cells being seeded too high so there were 
prematurely becoming confluent so there was probably an increase in cell death 
attributed to this. The floating and attached cells were harvested and immunoblotted 
for apoptosis indicator cPARP. The increase in apoptotic cell death was confirmed as 




The SKNAS cells however showed no significant change in the normalised red count 
after 73.5 hours of treatment with 10µM UNC0638 (Figure 4.7C). It did suggest there 
was more basal cell death in the SKNAS cells though as both the DMSO and 
UNC0638 treatments were higher than in the Kelly cells. This was not G9a inhibition 
associated apoptosis however as an immunoblot of the harvest cell lysates showed 
no change in cPARP in the treatment relative to the control (Figure 4.7D). 
Next, IMR32, Gimen, and SHSY5Y cells were treated with 5µM, 10µM, and 10µM 
UNC0638 respectively for 72 hours. These treatments were then harvested, and 
trypan blue inclusion assay was performed to determine a percentage cell death count. 
The IMR32 cells showed a significant increase (p<0.05, n=3) in percentage cell death 
with the UNC0638 treatment (Figure 4.8A). This was confirmed to be apoptosis after 
immunoblotting for cPARP, which increased after treatment.  
There were no significant changes (ns) in the percentage cell death in Gimen, (Figure 
4.8B) and SHSY5Y (Figure 4.8C) neuroblastoma when treated with UNC0638 relative 
to the DMSO control. There was also no change in cPARP protein in immunoblots of 
the harvest lysate indicating no apoptotic cell death. 
Immunoblots of lysates from harvested LAN-1, BE2C, and NGP neuroblastoma cell 
lines all treated with 10µM UNC0638 revealed that there was no change in cPARP in 
the LAN-1 and BE2C cells (Figure 4.8D) despite being MYCN-amplified. NGP however 
did increase in cPARP. This suggests that, in LAN-1 and BE2C at least, there may be 
an extra layer of regulation on apoptosis that is not present in the other MYCN-




Figure 4.7 – UNC0638 induces apoptosis in Kelly cells but not in SKNAS  
A- Normalised red object count shows that G9a inhibition in Kelly cells using 2.5µM UNC0638 
leads to apoptotic cell death due to a significant increase in the red object count, a proxy for 
cell death, after 18 hours (* p<0.05, *** p<0.01 n=2) between DMSO and UNC0638. Error bars 
show the SEM. B – Immunoblot of floating and adherent cells of treatments from A. cPARP is 
a marker for apoptosis and cell death. β-Actin is used as loading control. C – Normalised red 
object counts show G9a inhibition in SKNAS cells using 10µM UNC0638 does induce 
apoptotic cell death. Error bars show the SEM. D – Immunoblot of floating and adherent cells 
of treatments from C. cPARP is a marker for apoptosis and cell death. β-Actin is used as 




Figure 4.8 – Apoptotic cell death differs between MYCN-amplified genotypes 
A – Trypan blue inclusion assay of floating and adherent MYCN-amplified IMR32 cells 72 
hours after DMSO and 5µM UNC0638 treatments. This is used to measure the percentage 
cell death between the two treatments. Asterisk denotes significance (p<0.05, n=3). Error bars 
show the SEM. Immunoblot of floating and adherent cells of treatments. cPARP is a marker 
for apoptosis and cell death. β-Actin is used as loading control. B – Trypan blue inclusion 
assay of floating and adherent non-MYCN-amplified Gimen cells 72 hours after DMSO and 
10µM UNC0638 treatments. This is used to measure the percentage cell death between the 
two treatments. Ns denotes no significance (p>0.05, n=3). Error bars show the SEM. 
Immunoblot of floating and adherent cells of treatments. cPARP is a marker for apoptosis and 
cell death. β-Actin is used as loading control. C – Trypan blue inclusion assay of floating and 
adherent non-MYCN-amplified SHSY5Y cells 72 hours after DMSO and 10µM UNC0638 
treatments. This is used to measure the percentage cell death between the two treatments. 
Ns denotes no significance (p>0.05, n=3). Error bars show the SEM. Immunoblot of floating 
and adherent cells of treatments. cPARP is a marker for apoptosis and cell death. β-Actin is 
used as loading control. D – Immunoblot of floating and adherent cells of MYCN-amplified 
LAN-1, BE2C, and NGP treatments. cPARP is a marker for apoptosis and cell death. β-Actin 






4.7 G9a inhibition in S21N cells shows evidence of a synthetic lethal relationship 
between G9a and MYCN 
As there was some discrepancy as to whether G9a inhibition leads to apoptosis in 
MYCN-amplified neuroblastoma (Figure 4.8D) G9a inhibitor UNC0638 was tested in 
MYCN inducible S21N cell line. Cell proliferation was significantly (*** p≤0.01) reduced 
in both MYCN ON and OFF variants, (Figure 4.9A), after 46 hours of 5µM UNC0638 
treatment. When looking at the end timepoint specifically, the difference in the 
normalised object confluence is stark, (Figure 4.9B). Whilst the MYCN OFF version is 
still significantly (*** p<0.05, n=3) reduced in proliferation, the MYCN ON version has 
nearly halved. This suggests that G9a inhibition related reduction in cell proliferation 
is much more prominent in MYCN-amplified cell lines which fits with the trend shown 
throughout this chapter. 
DRAQ7 was also added to these treatments to assess apoptotic cell death in these 
MYCN variants. This output was measured by the IncuCyte imaging system as red 
object count. There was no significant change in the normalised red object count in 
the MYCN OFF S21N cells, yet there was a drastically significant increase in cell death 
after 22 hours in the MYCN ON variant (*** p<0.01) (Figure 4.9C). This shows that 
whilst there is no cell death in the MYCN OFF cells, there is apoptosis in the MYCN 
ON cells suggesting a synthetic lethal relationship between MYCN and G9a. This is 
confirmed by immunoblot of these samples (Figure 4.9D) which shows an increase in 
cPARP in the cells treated with UNC0638 with MYCN ON, but not in cells with MYCN 
OFF. As with the S21N cells depleted of G9a (Figure 3.7B) there is also a decrease in 
MYCN protein in the MYCN ON cells when treated with UNC0638 which suggests that 







Figure 4.9 – G9a inhibition preferentially kills MYCN-amplified S21N neuroblastoma 
cells 
A – Graph depicting normalised phase object confluence of the S21N cells with MYCN ON 
and MYCN OFF treated with DMSO and 2.5µM UNC0638 for 46 hours. Significance was 
evaluated at each time point by using T tests *** (p<0.01). Red (MYCN ON) and purple (MYCN 
OFF) lines are relative the respective DMSO treatments. Error bars show the SEM. B – Chart 
of normalised phase object confluence at the end time point of 46 hours of the cells from A. 
Asterisks denote significance (n= 3, * p<0.05, *** p<0.01). Error bars show the SEM. C – 
Normalised red object counts for the treatments from A. Significance was evaluated at each 
time point by using T tests *** (p<0.01). Error bars show the SEM. D – Immunoblot of S21N 
cells with MYCN OFF and MYCN ON from A probing for cPARP and MYCN. β-Actin is used 




In this chapter, a panel of four current small molecule inhibitors of G9a were tested for 
potency in a variety of neuroblastoma cell lines. Here it is shown that, despite all being 
labelled as potent and selective inhibitors, there is a difference in effectiveness 
between the drugs on the same neuroblastoma cell line. 
This chapter also shows that G9a inhibition by UNC0638 induces apoptotic cell death, 
but only in MYCN-amplified neuroblastoma. This goes someway to corroborating 
current literature in neuroblastoma as only one paper thus far shows G9a inhibition via 
BIX-01294 leads to apoptotic cell death in neuroblastoma through an increase in 
caspase 8/caspase 3 activity (260). However, Lu et al only look at one cell line, LA1-
55n which is derived from LA1-5s (a clonal subline of LAN-1) so is MYCN-amplified. 
This suggests that very little has been evaluated on G9a mediated apoptosis in 
neuroblastoma.  
G9a in the context of synthetic lethality has not been well characterised with only one 
study shown to utilise G9a inhibitors as a therapeutic agent in this manner. It has been 
suggested that immortalised breast luminal epithelial cell line MCF10A with an 
extended C-terminus frameshift mutant of transcription factor GATA3 (GATA3-ext) are 
more sensitive to G9a inhibition associated apoptosis via BIX-01294 and UNC0638 
than cells with wild type GATA3 (304). Mair et al don’t elaborate on a mechanism for 
this however. The data shown in this study suggests another  novel synthetic lethal 
relationship for G9a between it and MYCN. This exciting development shows new and 
novel research for high-risk neuroblastoma therapeutics. 
G9a inhibitors have been shown to induce apoptosis in other cancer cell lines too. 
There has been shown to be an increase in caspase activation and cPARP 24 hours 
after BIX-01294 treatment in human bladder cancer (305). Cui et al argues that BIX-
01294 treatment activates endoplasmic reticulum (ER) stress which has already been 
shown to induce apoptosis after long-term stress (306). This ER stress could also be 
an off-target effect of the BIX-01294 drug, however the identification of early 
responding genes after G9a depletion in bladder carcinoma and lung adenocarcinoma 
suggests a more reliable dataset. Furthermore, microarray analysis of was used to 
identify downstream targets of G9a. A known positive regulator of apoptosis in cancer 
cells, E3 ubiquitin ligase SIAH1, was found to be upregulated following G9a depletion 
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(149, 307). Cho et al show in multiple lung adenocarcinoma, lung squamous cell 
carcinoma, small cell lung cancer, and bladder cancer cell lines that G9a binds to the 
promoter region of SIAH1 and represses it through H3K9 di-methylation thus helping 
to repress apoptosis. 
G9a can also mediate tumour metastasis with G9a expression shown to correlate with 
the invasive potential of lung adenocarcinoma; increased expression typifies 
increased invasiveness (143). Furthermore, results from Chen et al show the histone 
methyltransferase activity of G9a is necessary for the invasive phenotype of lung 
cancer cells. G9a directly downregulates epithelial cell adhesion molecules (Ep-CAM) 
by recruiting a complex of repressor proteins to the Ep-CAM promoter (143). G9a 
knockdown was able to demethylate the promoter and increase Ep-CAM expression. 
They did not use any small molecule inhibitors of G9a in this study, but abolition of 
G9a’s catalytic activity impedes invasiveness suggesting small molecule inhibitors 
could also upregulate Ep-CAM expression to reduce this invasive phenotype. 
An issue with these inhibitors are that they inhibit the SET domains of both G9a and 
GLP since they share approximately 80% sequence identity (75, 165), therefore it is 
difficult to determine if there is a response to inhibiting one of these proteins separately 
since they possess distinct physiological and pathophysiological functions (308). 
Whilst GLP and G9a have similar non-histone targets such as reptin (132) and sirtuin 
1 (309), they also have different non-methylation targets and can recognise different 
substrates through their ankyrin repeat domains. For example, GLP ankyrin repeats 
act as an effector domain for K310 mono-methylated transcription factor RelA to 
repress NF-κB signalling by binding at target genes to generate a silent chromatin 
state (310). G9a is shown to not recognise this site. Recently, a GLP specific 
compound MS012 has been manufactured that has over a 140-fold selectivity for GLP 
over G9a (311). Alongside GLP depletion, this inhibitor could be used to further define 
the differing spheres of influence G9a and GLP have over targets and gene regulation. 
This all suggests the importance of G9a in being able to regulate cellular processes 
like apoptosis in multiple cancer cell lines and therefore suggests why G9a should be 
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As a lysine methyltransferase, G9a has been associated with various cellular 
processes. These involve differentiation (119), proliferation (312, 313), and 
senescence (314). As discussed previously, G9a can act as a transcriptional regulator. 
G9a deposits methylation marks to target lysine residues which results in mono-/di-
methylation marks on H3K9 (113). These deposited marks are associated with active 
and repressed gene transcription respectively. G9a also regulates gene expression 
through methylation of non-histone targets; G9a automethylates its N-terminus to 
recruit binding partner HP1. This either activates gene transcription such as a subset 
of glucocorticoid genes (315), or represses gene transcription by HP1 recruitment of 
other transcriptional repressors like HDAC1 and DNMT1 (129). G9a also methylates 
transcription factor C/EBP β to repress myeloid gene activation (139). This all suggests 
that G9a can switch between being a transcriptional activator or a repressor depending 
on either its methylation target; histone and non-histone, and the degree of 
methylation, or its binding partner via the ankyrin repeat domain. 
MYCN is a transcription factor that has many target genes related to many functions 
within the cell such as cell cycle and apoptosis. These targets are either be expressed 
or repressed by MYCN activity. MYCN-amplification occurs in about 50% high-risk 
poor prognosis neuroblastoma (211), and high MYCN protein is also closely 
associated with poor prognosis (297). MYCN-amplification has been suggested to 
correlate with cells failing to arrest correctly in G1 phase (316), due to the upregulation 
of MYCN target cyclin D2 (317). This suggests that MYCN-amplification is causing an 
increase in the MYCN upregulated targets and a decrease in repressed targets to help 
drive tumourigenesis. Therefore, being able to manipulate MYCN protein stability 
would help to reverse this. 
MYCN protein stability can be regulated by various post-translational modifications. 
For example, a cascade of phosphorylation events at specific residues consequently 
leads to the ubiquitination and proteasomal degradation of MYCN protein (227). 
Moreover, it has been suggested that di-methylation by arginine methyltransferase 
PRMT5 can increase MYCN protein stability (229). These both suggest how post-
translational modifications can affect MYCN stability to either increase or decrease 
MYCN protein levels. 
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Previous unpublished RNA sequencing (RNAseq) data from Dr. Malik and Dr. Szemes 
assessed the impact on gene expression between resistant non-MYCN-amplified 
SKNAS cells and sensitive MYCN-amplified LAN-1 cells treated with BIX-01294. 
These identified changes in gene expression between the MYCN-amplification 
statuses, as well genes that were being up- and downregulated by G9a. Some of these 
genes have not been associated with G9a regulation before and thus will be explored 
within this chapter. 
In addition, in this chapter, it is shown that G9a can regulate MYCN oncoprotein in 
MYCN-amplified neuroblastoma and can therefore repress and re-express 
downstream MYCN targets. One of these targets is suggested to be little known pro-
apoptotic factor BOK which is suggested here to have a key role in regulating 
apoptosis in G9a inhibited MYCN-amplified neuroblastoma. This therefore 
emphasises the importance of G9a as a novel target in high-risk neuroblastoma 
therapeutics. 
5.2 Discovery of novel repressed G9a targets 
A selection of genes from the RNAseq data set which had the highest fold change in 
expression are shown in Figure 5.1A. These suggest that whilst they are all 
upregulated in LAN-1 cells, AMHR2 (anti-Mullerian hormone receptor II) and BOK 
(BCL-2 related ovarian killer) show no change and downregulation respectively in the 
resistant SKNAS cells suggesting that MYCN may help to regulate these genes. These 
genes have not been shown to be regulated by G9a in published literature to date. 
Furthermore, using the SEQC-498 database from the Genomic Analysis and Visual 
Platform R2, Kaplan-Meier curves show that high expression of these genes are 
markers for good prognosis (p values indicated in figure 5.3A). 
Since BIX-01294 is not a reliable small molecular inhibitor, these genes were re-
probed in neuroblastoma cell lines, two sensitive cell lines Kelly and LAN-1, and two 
resistant SKNAS and GIMEN, treated with UNC0638 for 24 hours (Figure 5.1B) to 
determine if these are true G9a repressed targets as suggested by the RNAseq data. 
First FABP3, BOK, and AMHR2 were assessed (Figure 5.1 B-D). FABP3 (Fatty acid 
binding proteins 3) is upregulated in all cell lines with MYCN-amplified Kelly and LAN-
1 having a drastically increased relative change, around 60-fold, comparative to the 
non-MYCN-amplified despite similar basal levels. BOK was very significantly 
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upregulated in Kelly and LAN-1 cells, whereas in SKNAS and Gimen cells there is no 
significant fold change. AMHR2 was significantly upregulated in with MYCN-amplified 
cell lines Kelly and LAN-1, with around a 10-fold increase in Kelly. There was no 
significant change in the non-MYCN-amplified cells.  
Aldo-keto reductase family AKR1C1, AKR1C2, and AKR1C3 were all significantly 
upregulated in Kelly, LAN-1, and SKNAS cells but there was no increase in Gimen 
cells (Figure 5.1 E-G). FLCN (folliculin) is very significantly up regulated in Kelly, LAN-
1, but there is no significant change in SKNAS cells and a significant downregulation 
in Gimen cells (Figure 5.1 F). CCBE1 (Collagen and calcium-binding epidermal growth 
factor domains 1) is very significantly increased in all four cell lines suggesting it as a 
repressed target of G9a histone methyltransferase domain (Figure 5.1 I). 
This data suggests that CCBE1 and FABP3 are genes normally repressed by G9a 
histone methyltransferase activity in neuroblastoma, with FABP3 strongly increased in 
MYCN-amplified cell lines. The AKR1C1-3 family of genes were upregulated in three 
of the four cell lines with no change in Gimen cells suggesting these cells have an 
additional layer of regulation. BOK, FLCN and AMHR2 relative expression is 
significantly increased in MYCN-amplified Kelly and LAN-1 and there is no change in 





Figure 5.1 – G9a inhibition regulates novel gene targets 
A – Table showing eight genes that were of interest following RNA sequencing data from LAN-
1 and SKNAS neuroblastoma cells treated with BIX-01294 previously produced by members 
of the laboratory. This assesses the fold change in gene expression (log2), if high expression 
is good for prognosis, and the respective p values from the SEQC-498 database; both raw 
and Bonferroni. B-I – qRT-PCR of these eight genes (names labelled above each chart) in 
Kelly, LAN-1, SKNAS, and Gimen neuroblastoma cells treated with 5µM (Kelly) and 10µM 
(LAN-1, SKNAS, Gimen) for 24 hours cells. Expression is relative to TBP. Significance is 
measured by unpaired T test relative to DMSO control (ns p>0.05, * p<0.05, *** p<0.01, n=3). 
Error bars show the SEM. 
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5.3 Separate MYCN and G9a depletion increases BOK expression 
From these genes of interest, BOK was evaluated in further detail as it is a pro-
apoptotic factor, and its increase in expression solely in MYCN-amplified Kelly and 
LAN-1 may suggest why apoptotic cell death has solely occurred in MYCN-amplified 
cell lines thus far. 
To assess if BOK is regulated by G9a and MYCN, both G9a and MYCN were 
individually depleted in Kelly cells. Immunoblot of these transfections show effective 
knockdowns (Figure 5.2A), with both leading to an increase in BOK protein alongside 
an increase in cPARP. MYCN has been shown to regulate apoptosis by repressing 
pro-apoptotic genes such as p53 and CASP8 to help the cancer survive (184, 232, 
233) so the increase in cPARP makes sense. Furthermore, there is a consistent and 
significant increase in relative fold expression of BOK of around 1.5 times in effective 
G9a and MYCN knockdowns, Figure 5.2B and C respectively. 
Next, G9a was depleted in non-MYCN-amplified SKNAS as it was hypothesised that 
there would be no change in BOK protein since A) there was no change in BOK 
transcript after UNC0638 treatment (Figure 5.1B), and B) there was no cPARP 
increase in SKNAS cells previously depleted of G9a, (Figure 3.6). Immunoblot of 
SKNAS cells treated with siG9a showed no change in BOK or cPARP after effective 
knockdown (Figure 5.3A). Furthermore, there is no significant change in relative fold 




Figure 5.2 – G9a and MYCN depletion increase BOK expression 
A – Kelly cells depleted of G9a and MYCN. Immunoblot shows effective depletion of G9a and 
MYCN, alongside increase in cPARP and BOK in both transfections. β-Actin is used as a 
loading control. B – qRT-PCR of BOK and G9a genes in Kelly transfected with siG9a. Fold 
change is relative to TBP. Significance is measured by unpaired T test (*** p<0.01, n=3).  
C – qRT-PCR of BOK and MYCN genes in Kelly transfected with siMYCN. Fold change is 
relative to TBP. Significance is measured by unpaired T test (* p<0.05, *** p<0.01, n=3). Error 
bars show the SEM. 
 
Figure 5.3 – G9a depletion does not change BOK expression in SKNAS 
A – SKNAS cells depleted of G9a. Immunoblot shows effective depletion of G9a increase in 
cPARP and BOK in both transfections. β-Actin is used as a loading control. B – qRT-PCR of 
BOK and G9a genes in Kelly transfected with siG9a. Fold change is relative to TBP. 
Significance is measured by unpaired T test (ns p>0.05, n=3). Error bars show the SEM. 
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5.4 G9a inhibition increases BOK protein in tested MYCN-amplified cell lines 
Next, it was assessed if treatment with UNC0638 would illicit the same increase in 
BOK protein as previously shown with BOK mRNA. MYCN-amplified Kelly and 
IMR32 cells and non-MYCN-amplified SKNAS and Gimen cells were treated with 
UNC0638 for 72 hours. 
Immunoblotting of floating and adherent treated cells shows an increase in BOK 
protein in both Kelly and IMR32 cells following G9a inhibition, but not in the SKNAS 
and Gimen cells. This is mirrored by the changes or lack thereof in cPARP in the 
respective cell lines. BOK also seemingly decreases in SKNAS cells which is reflected 
in the decrease in cPARP (Figure 5.4) suggesting that BOK is an independent 
apoptotic regulator. 
BOK has also been suggested to play a role in regulating macro-autophagy 
(autophagy) as increased BOK expression following oxidative stress has been shown 
to induce autophagy directly, as well as indirectly by a mechanism that involves BOK 
sequestration of MCL-1 to free Beclin-1 and thus induce autophagy (318). This 
suggests that BOK has a role in both type I (apoptosis) and II (autophagy) programmed 
cell death. Therefore, LC3B, an indicator of autophagy, was also probed for.  
Kelly cells, which has easily inducible apoptosis, and LAN-1 cells, with seemingly 
methylated BOK, were tested after UNC0638 treatments; if there is still autophagy in 
LAN-1 cells with no BOK expression then this would suggest that BOK is not involved 
in autophagy following G9a inhibition. Cells were treated for 24 and 72 hours with 
UNC0638 (Figure 5.5). In Kelly cells, there is a consistent increase in BOK, cPARP, 
and LC3B. However, the LAN-1 cells show no BOK and as a result there is no change 
in cPARP. However, there is an increase in LC3B which suggests that whilst G9a 
inhibition seemingly induces both apoptotic and autophagy, BOK is not involved in the 





Figure 5.4 – BOK protein increases in MYCN-amplified neuroblastoma 
Immunoblots for BOK and cPARP protein expression in a panel of MYCN- and non-MYCN-
amplified neuroblastoma cell lines treated with UNC0638 for 72 hours. Kelly was treated with 




Figure 5.5 – BOK protein induction correlates with apoptosis and not autophagy 
Immunoblots for BOK, cPARP, and LC3B protein expression in Kelly and LAN-1 
neuroblastoma cell lines. Kelly was treated with 5µM and LAN-1 with 10µM UNC0638 and 
harvested at 24 hours and 72 hours. β-Actin is used as a loading control.  
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5.5 BOK mRNA and protein expression is decreased in poor prognostic and 
MYCN-amplified neuroblastoma 
High expression of pro-apoptotic BCL-2 family BAK has been shown correlate with 
favourable prognosis in lung cancer (319) and colorectal cancer (320). As BOK is also 
a pro-apoptotic BCL-2 family member, this would imply that it would act similar in a 
similar manner with regards to prognosis. Carberry et al show that BOK protein can 
be used as a prognostic marker as stage II and III colorectal cancer patients possess 
decreased BOK protein relative to normal tissue suggesting BOK as a good prognostic 
marker (320). However, they also suggest that BOK mRNA does not correlate with 
prognosis, and that increased BOK protein levels actually associated with earlier 
disease recurrence and reduced overall survival (320), suggesting BOK is actually 
poor prognostic. Therefore, BOK expression and prognosis was assessed in 
neuroblastoma using the three different neuroblastoma datasets from the Genomic 
Analysis and Visual Platform R2 (http://r2.amc.nl) similar to chapter 3.2. 
BOK was assessed to determine if high expression was considered a good or a bad 
prognostic indicator in neuroblastoma. BOK mRNA was expression was mapped to 
the outcome of each patient (Figure 5.6A). All three databases indicated that high BOK 
mRNA expression correlated with a significant increase in overall survival probability. 
Versteeg- 88 showed 58/80 patient tumour samples tested presented a high overall 
survival probability relative to tumours with low BOK expression (Bonferroni p=5.7e-5). 
SEQC- 498 had a comparable result with 351/498 being in the high expression 
(Bonferroni p= 6.8e-19) and Kocak- 649 had 408/476 (173 samples omitted as they 
lacked survival information) in the high expression, high outcome bracket (Bonferroni 
p= 5.0e-21). These are all highly significant with the overall survival probability not 
below 0.8 (80%) in the high BOK expression across the patients across the three 
databases. This data indicates that BOK is correlated with outcome and that high BOK 
expression is favourable, which goes against what Carberry et al have presented 
(320). When BOK expression was limited to patients with non-MYCN-amplification 
only, this still shows a significantly favourable outcome with high BOK expression 
(Bonferroni p= 0.049, 1.4e-5, 2.5e-7 respectively) (Figure 5.8B). 





Figure 5.6 – High BOK mRNA expression correlates with good prognosis in 
neuroblastoma 
A – Kaplan-Meier survival curves of neuroblastoma show a positive relationship between high 
BOK mRNA expression and good prognosis. The blue and red lines represent high and low 
BOK mRNA expression respectively, whilst n represents the number of tumours in each 
category. This correlation was shown in three separate named tumour array datasets. 
Versteeg-88 analysis derives from microarray data analysing eighty eight human tumours 
(297). SEQC- 498 is derived from RNA sequencing data of 498 neuroblastoma (321). Kocak-
649 is generated using 44K oligonucleotide microarrays of neuroblastoma tumours and cell 
lines. In the Kocak-649 dataset, only 476 of the 649 neuroblastoma samples were analysed 
as only these had survival information available (222). B – Kaplan-Meier survival curve from 
the databases shown in A were refined to only include tumours with non MNA states. This 
showed that there is a positive relationship between high BOK mRNA expression and good 
prognosis after poor prognostic indicator MYCN-amplification is taken out. The blue and red 
lines represent high and low BOK mRNA expression respectively, whilst n represents the 




Next, BOK expression was compared between MNA and non-MNA neuroblastoma 
tumours to examine the relationship in the same three datasets. Boxplots produced 
from the R2 platform using the datasets (Figure 5.7A) shows that there is a consistent 
significant decrease in BOK mRNA in MNA tumours relative to non-MNA tumours 
(p=8.4e-5, 4.4e-52, 2.8e-49 respectively). 
Because of the correlation at the RNA level, it was necessary to determine if this was 
true at the protein level too. A panel of protein lysates from five MNA, three non-MNA 
neuroblastoma, and two disease-free cell lines were immunoblotted for BOK and 
MYCN (Figure 5.7B). β-actin was used a loading control. MYCN protein was 
overexpressed in all the MNA cell lines. There was a lower expression of BOK protein 
in these cell lines relative to the non-MNA. This relationship was quantified using semi-
quantitative densitometry of the immunoblots using image J (Figure 5.7C). Relative 
BOK was quantified to β-actin. Relative BOK levels were shown to be significantly 
lower in the MYCN-amplified cell lines relative to non-MNA and disease-free cell lines 
(* p<0.05). BOK was ubiquitously expressed in all the non-MNA cell lines tested unlike 
in the MNA cell lines where there is no BOK protein in cell lines LAN-1 and BE2C cell 
lines. BOK gene has been shown to be methylated in colorectal cancer (320), so BOK 
may be methylated in these two cell lines. This would suggest why no apoptosis was 
seen in these two cell lines when treated with UNC0638 as there was no induction of 
BOK. 
Overall, examination of BOK and MYCN mRNA and protein in neuroblastoma cell lines 
suggests that BOK is more highly expressed in non-MNA cells suggesting that MYCN 





Figure 5.7 – Low BOK protein expression correlates with MYCN protein 
A – Lower BOK mRNA expression is observed in MNA neuroblastoma relative to non MNA. 
This correlation was shown in three separate named tumour array datasets previously 
mentioned in Figure 5.4. The red and green colours represent MNA and non MNA 
respectively. The p-values are calculated by one-way ANOVA (Analysis of Variance) on R2.    
B – Immunoblot of BOK protein expression in a panel of MYCN- and non-MYCN-amplified 
neuroblastoma cell lines. β-Actin is used as a loading control. Representative of two biological 
replicates. C – Relative BOK expression is higher in MNA neuroblastoma. Box plot of relative 
BOK protein is generated from semi-quantitative densitometry of blot from A. BOK expression 
was normalised to β-Actin.  
 
5.6 BOK depletion rescues Kelly cells treated with UNC0638 from apoptosis  
It has been suggested that BOK depletion by short hairpin (sh) RNA in human 
granulosa tumours is effective at significantly inhibiting caspase-3/7 activation after 
addition of various apoptosis-inducing factors, thus protecting the cells from apoptotic 
cell death (322). As the data in this study suggests G9a inhibition by UNC0638 induces 
apoptosis in MYCN-amplified cells, it was therefore hypothesised that BOK depletion 
may rescue these cells from apoptotic cell death after G9a inhibition; Kelly cells were 
treated with UNC0638 with and without BOK depletion to assess changes in apoptotic 
cell death. 
DRAQ7 was added to Kelly cells transfected with siNEG and siBOK and treated with 
DMSO and UNC0638 to assess apoptotic cell death. This was measured by the 
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IncuCyte imaging system as red object count. The normalised red count shows that 
whilst there is a very significant increase in siNEG UNC0638 relative to siNEG DMSO 
control (pink line), there is no significant change between the siBOK DMSO and siBOK 
UNC0638 treatments over the 48-hour time course (Figure 5.8A).  
This is further supported by trypan blue inclusion assay of the harvested cells with the 
same treatment. In the UNC0638 treated cells with wild type BOK, there was a very 
significant increase in percentage cell death relative to the negative small molecule 
inhibitor control DMSO (Figure 5.8B), similar to that seen in the previous chapter. 
However, in the BOK depleted cells, there was a no significant change in percentage 
cell death between the siBOK DMSO and siBOK UNC0638 treatments (Figure 5.8B) 
suggesting BOK depletion has rescued the cells from G9a inhibition-associated 
apoptosis. This is verified by immunoblot (Figure 5.8C) as there is an increase in BOK 
and cPARP in the siNEG transfected cells when treated with UNC0638, but no change 
in either following effective BOK depletion. 
Next, other pro-apoptotic factors BAX and BAK were re-probed in the treatments used 
in the Kelly cells from figure 5.6. This would determine if BOK acted independently of 
the other factors as highlighted by Einsele-Scholz et al (323) and Llambi et al (38). 
After 72 hours of UNC0638 treatment, there is no change in either BAX or BAK protein 
expression despite the obvious increase in BOK and cPARP (Figure 5.8D). This 
suggests that the mechanistic effect of G9a inhibition on apoptosis is through a 
pathway that specifically targets BOK. 
Therefore, this data suggests that increase in pro-apoptotic factor BOK protein caused 
by G9a histone methyltransferase activity inhibition is necessary for apoptotic cell 






Figure 5.8 – BOK depletion rescues Kelly cells from apoptosis following G9a inhibition 
A – Normalised red object counts between Kelly neuroblastoma cells treated with DMSO and 
UNC0638 with wild type and depleted BOK. Kelly cells were transfected with siBOK for 36 
hours before being treated with negative control DMSO and 5µM UNC0638 for 48 hours. 
Significance was evaluated at each time point by using T tests (*** p<0.01, n=2). Error bars 
show the SEM. B – This chart shows the percentage cell death changes. Floating and 
attached cells were the harvested and trypan blue inclusion assay was performed to count the 
dead cells. Significance is measured by unpaired T test (n=2, *** p<0.01, ns p>0.05). Error 
bars show the SEM. C – Immunoblot of treatments from A to confirm BOK depletion and 
apoptosis induction via cPARP increase. β-Actin was used as a loading control. D – 
Immunoblot of treatments in Kelly cells from Figure 5.6. These were probed for other pro-
apoptotic factors BAX and BAK to determine if these were also increased following UNC0638 
inhibition for 72 hours at 5µM. β-Actin was used as a loading control.  
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5.7 BOK depletion and inhibits cell proliferation 
There was no significant change in the basal percentage cell death between the siNEG 
and siBOK transfections treated with DMSO despite a suggested decrease in cPARP 
(Figure 5.8B). This suggests that this increase in BOK expression is driving the 
apoptotic cell death, and it is not just the mere presence of BOK, as overexpression 
has been shown to increase its pro-apoptotic function (324-328). Furthermore, it is 
assumed that BOK is a potential tumour suppressor gene following its induction after 
G9a inhibition with its role in inducing apoptosis. Therefore, the effect of BOK depletion 
on cell growth was assessed to determine if BOK is a potential tumour suppressor; 
cell growth should increase in cells with BOK depleted if BOK acted as a tumour 
suppressor gene. 
BOK was depleted in Kelly and IMR32 cells. There is a significant reduction in 
percentage confluence in Kelly cells from 88 hours, and very significant from 100 hours 
(Figure 5.9A). Immunoblot of these lysates shows effective depletion of BOK (Figure 
5.9B). Similarly, in IMR32 there is a significant reduction in percentage confluence 
from 14 hours and very significantly from 58 hours (Figure 5.9C). Effective BOK 
depletion is confirmed by immunoblot (Figure 5.9D). 
This data suggests that BOK depletion, in cell lines with relatively low levels of BOK 
protein expression, negatively impacts percentage confluence suggesting that BOK 
not only has a role in promoting cell proliferation, but that its tumour suppressor 







Figure 5.9 – BOK depletion decreases cell proliferation 
A – Graph depicts the normalised percentage phase object confluence as a proxy of cell 
growth in Kelly cells. The cells were transfected with siRNA at 25nM and incubated for 108 
hours. The significant red line below the graph shows significance (n=2, * p<0.05) after 88 
hours. After 100 hours, the difference is very significant- maroon line (n=2, *** p<0.01). Error 
bars show the SEM. B – Immunoblot to confirm BOK depletion. β-Actin is used as loading 
control. C – Graph depicts the normalised percentage phase object confluence as a proxy of 
cell growth in IMR32 cells. The cells were transfected with siRNA at 25nM and incubated for 
72 hours. The significant red line below the graph shows significance (n=2, * p<0.05) after 14 
hours. After 58 hours, the difference is very significant- maroon line (n=2, *** p<0.01). Error 






5.8 BOK is a novel differentiation modulator in Kelly and IMR32 neuroblastoma 
When looking at the photomicrographs of IMR32 and Kelly cells with BOK depleted 
from Figure 5.9, there is a dramatic increase in neuritogenesis in both cell lines; a 
marker of differentiation. 
This differentiation effect is prominent in IMR32 cells with BOK depleted. The 
photomicrographs (Figure 5.10A) show a marked increase in the neuritogenesis 
between the negative control and BOK depleted cells. The main body of the cells are 
smaller, but the neurite lengths are significantly longer. As these cells were imaged 
using the live cell imaging system IncuCyte Zoom, an analysis job was performed to 
measure the change in length of these neurites between the negative control and the 
BOK depleted cells. The change in normalised neurite length is very apparent with 
normalised neurite length of the BOK depleted cells being nearly two-fold the negative 
control after 72 hours (Figure 5.10B). There is a significant difference after 50 hours, 
which is very significant after 56 hours following effective BOK depletion (Figure 
5.10C). Moreover, neurite length initially shortens until around 24 hours before they 
lengthen in both treatments which mirror until around the 48-hour mark. This was 
consistent across the two biological replicates, suggesting that it takes time for the 
effect of BOK depletion to manifest itself in this differentiation effect. 
In Kelly cells, the morphology of the cells also changes following BOK depletion as 
they become phenotypically different (Figure 5.11A). The cells with depleted BOK 
become much thinner and there are more neurites extending from the poles of the 
cells. This increase is similarly shown in the normalised neurite length graph of the 
treated Kelly cell lines showing an increase in neuritogenesis and differentiation of the 
cells (Figure 5.11B). There is no significant change in normalised neurite length until 
48 hours when there is a dramatic and significant increase. This becomes very 
significant after 68 hours. Immunoblot of these cell protein lysates show effective 
depletion of BOK in these treatments (Figure 5.11C). 
This differentiation phenotype was not observed in SKNAS cells effectively depleted 
of BOK despite showing a decrease in cell proliferation (data not shown). This 
suggests that BOK has a proliferative effect in cells, and this is not just an artefact of 




Figure 5.10 – BOK depletion differentiates IMR32 cells after 50 hours 
A – Photomicrographs at 10x objective magnification of IMR32 cells transfected with negative 
control (siNEG) and BOK siRNA for 72 hours. These show the phenotype of neuritogenesis 
in the siBOK cells. B – Graph displays normalised neurite length changes over the time course 
of Kelly cells. There is a significant increase after 50 hours – red line (n=2, * p<0.05), and very 
significant after 56 hours – maroon line (n=2, *** p<0.01). Error bars show the SEM. C – 




Figure 5.11 – BOK depletion differentiates Kelly cells after 48 hours 
A – Photomicrographs at 10x objective magnification of Kelly cells transfected with negative 
control (siNEG) and BOK siRNA for 108 hours. These show the phenotype of neuritogenesis 
in the siBOK cells. B – Graph displays normalised neurite length changes over the time course 
of Kelly cells. There is a significant increase after 48 hours – red line (n=2, * p<0.05), and very 
significant after 68 hours – maroon line (n=2, *** p<0.01). Error bars show the SEM. C – 
Immunoblot to confirm BOK depletion. β-Actin is used as loading control.  
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5.9 G9a regulates MYCN protein in Kelly cells 
Since there has been shown to be a strong association between G9a and MYCN 
throughout this study, the effect on MYCN mRNA and protein following G9a depletion 
was examined.  
Effective G9a depletion showed a significant reduction in MYCN at the protein level 
(Figure 5.12A). However, at the RNA level, despite an effective and significant 
knockdown of around 50% in two biological replicates, there is not a significant relative 
fold change in MYCN expression (Figure 5.12B). This suggests that the MYCN 
reduction shown is due to protein regulation by G9a. 
To determine if this regulation was necessitated by the histone methyltransferase SET 
domain of G9a, small molecule inhibitor UNC0638 was added to Kelly and LAN-1 (a 
progenitor of the LA1-55n cells used by Lu et al) neuroblastoma at 5µM and 10µM 
respectively for 24 hours (Figure 5.12C). Again, there was a clear decrease in MYCN 
protein relative to the DMSO control. Furthermore, when looking at the mRNA level, 
there is no significant change in the relative MYCN expression in these cell lines 
(Figure 5.12D).  
Overall, this data suggests that G9a histone methyltransferase domain is necessary 
for MYCN protein stability and regulation, and inhibition by small molecule inhibitor 




Figure 5.12 – MYCN is regulated by G9a at the protein level 
A – Immunoblot of Kelly cells transfected with siNEG (negative control) and siG9a at a 
concentration of 25nM for 72 hours. Attached and floating cells were harvested and 
immunoblotted for G9a and MYCN. β-Actin was used as a loading control. B – qRT-PCR of 
MYCN and G9a in Kelly cells after 72-hour siG9a transfection. Expression change is relative 
to TBP. Fold change is relative to negative control. Significance is measured by unpaired T 
test (*** p<0.01, ns p>0.05, n=2). Error bars show the SEM. C – Immunoblot of Kelly and LAN-
1 cells treated with 5µM and 10µM respectively for 24 hours. Attached and floating cells were 
harvested and immunoblotted for MYCN. β-Actin was used as a loading control. D- qRT-PCR 
of MYCN in Kelly and LAN-1 cells treated with 5µM and 10µM respectively for 24 hours cells. 
Fold change is relative to TBP. Significance is measured by unpaired T test (ns p>0.05, n=3) 
Error bars show the SEM.  
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5.10 G9a inhibition can regulate MYCN targets 
Since MYCN protein was downregulated after inhibition with UNC0638, this suggests 
that MYCN’s ability as a transcriptional regulator may be diminished therefore re-
expressing previously repressed targets and repressing induced targets. Therefore, 
mRNA expression fold change of a few suggested MYCN targets were assessed. The 
targets tested were Clusterin (CLU), CASP8, and ALK. CLU is a molecular chaperone 
and tumour suppressor that is downregulated by MYCN binding to CLU promoter to 
recruit repressive complexes (242). CASP8 is a member of the caspase family 
involved in apoptosis. CASP8 has been shown to be a direct target of c-MYC in 
lymphoblastoid cells (329) and MYCN/MAX dimer has been shown to bind to CASP8 
promoter after demethylation treatment in LAN-1 cells (330). ALK promoter has a non-
canonical E-box upstream of the transcription start site which MYCN can bind to 
upregulate ALK transcription (213).  
Four neuroblastoma cell lines, Kelly, LAN-1, SKNAS, and Gimen (two MYCN-amplified 
and two non-MYCN-amplified respectively) were all treated with UNC0638 for 24 
hours. The relative fold change in the mRNA expression of the three genes was then 
measured (Figure 5.13). In the MYCN-amplified Kelly and LAN-1 neuroblastoma, fold 
change in CLU expression increased significantly after G9a inhibition, whereas the 
was no significant change in the non-MYCN-amplified SKNAS and Gimen cells. 
Similarly, CASP8 also significantly increases in the Kelly and LAN-1 cells after G9a 
inhibition. In SKNAS cells, there is a significant decrease in fold expression change, 
and no significant decrease in Gimen cells. ALK fold expression change very 
significantly decreases in both Kelly and LAN-1, but also in SKNAS cells. Gimen cells 
have no significant decrease. This all suggests that CLU and CASP8 are upregulated 
following G9a inhibition in only MYCN-amplified cells, suggesting this is due to 
downregulation of MYCN protein on these promoters. Moreover, ALK fold expression 
change decreases in three of the cell lines (no significant change in Gimen) and there 
is no pattern between the MYCN and non-MYCN-amplified cell lines. This suggests 




Figure 5.13 – Treatment by G9a small molecule inhibitor regulates suggested MYCN 
targets 
qRT-PCR of A – Clusterin (CLU), B – ALK, and C – CASP8, in Kelly, LAN-1, SKNAS, and 
Gimen cells treated 5µM (Kelly) and 10µM (LAN-1, SKNAS, Gimen) UNC0638 for 24 hours 
cells. Fold change is relative to TBP. Significance is measured by unpaired T test (ns p>0.05, 




The aim of this chapter was to assess the gene and protein regulatory effects G9a 
inhibition has in both MYCN-amplified and non-MYCN-amplified neuroblastoma. From 
looking at gene expression changes highlighted by the previous RNAseq analysis, it 
was verified that G9a has a role gene regulation in neuroblastoma as G9a inhibition 
was able to up and downregulate expression of certain genes. 
There were four groups of genes shown to be regulated by G9a in a heatmap of the 
RNA sequencing, not shown, with 1) genes upregulated and 2) downregulated 
following BIX-01294 treatment, and then 3) genes upregulated and 4) downregulated 
between the MYCN-amplified LAN-1 and non-MYCN-amplified SKNAS cells. This 
suggests that G9a not only had its own genes to regulate but could also modulate 
MYCN repressed and activated targets too. The novel repressed G9a targets in this 
chapter are CCBE1, FLCN, AMHR2, and FABP3. ChIP would be needed to ascertain 
if the promoters of these genes are directly repressed by G9a or if they are indirect 
downstream targets. 
This chapter has shown that G9a depletion and inhibition in tested MYCN-amplified 
cell lines has the ability to reduce MYCN protein but not MYCN mRNA. This suggests 
that G9a activity can stabilise MYCN at the protein level either through direct 
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methylation or methylation of a binding partner. In addition, regulation of suggested 
MYCN targets ALK, CLU, and CASP8 is shown following G9a inhibition suggesting 
that G9a inhibition can also control expression of MYCN targets. In the context of 
neuroblastoma, G9a and MYCN regulation has only been suggested in one study Lu 
et al, as mentioned previously. The data shown in this chapter is more comprehensive 
and thorough than that currently published as it shows MYCN protein depletion in 
multiple cell lines after both G9a depletion and inhibition using a more reliable G9a 
inhibitor. Therefore, this data suggests that G9a is a viable therapeutic target in 
MYCN-amplified tumours. 
MYCN-amplification and overexpression also afflict other types of cancer with an 
aggressive phenotype. MYCN is found to be overexpressed in a vast majority of 
retinoblastoma and is amplified in a small subset too (331-333). In addition, MYCN is 
amplified in 15-20% of small-cell lung cancer (334, 335) which are suggested to have 
a poor response to chemotherapeutic treatments whilst having a very quick growth 
rate (336). MYCN overexpression has also been reported in a subset of breast cancers 
(337) and Wilms’ Tumour (338). This suggests that MYCN-amplification and 
overexpression is more prevalent than being restricted to high-risk neuroblastoma 
therefore being able to inhibit and decrease MYCN protein through the use of G9a 
small molecule inhibitors would benefit a much wider patient set.  
G9a has also been shown to stabilise other MYC family member c-MYC (MYC) in 
Abelson murine leukaemia virus-induced tumour (339). Cycloheximide (CHX) chase 
assay of MYC in wildtype and G9a depleted Raw264.7 cells also showed the rate of 
MYC decay was increased four-fold in G9a depleted cells (339). This G9a stabilising 
effect matches data presented here as there is a decrease in MYCN protein after both 
G9a depletion and inhibition suggesting G9a has a similar destabilising effect on 
MYCN. Furthermore, qRT-PCR results have shown an increase in MYC expression 
following G9a knockdown (339), which is similar to the results presented in this chapter 
as there is no decrease in MYCN mRNA expression after separate G9a depletion and 
inhibition, therefore implying G9a does not regulate gene expression of MYC family 
members MYC and MYCN. 
This stabilising effect G9a imparts on MYCN would suggest why there is a difference 
in gene regulation between MYCN-amplified LAN-1 and non-MYCN-amplified SKNAS 
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cells following G9a inhibition as G9a inhibition destabilases MYCN protein in amplified 
cell lines disrupting its regulatory effect on MYCN targets. 
The novel tumour suppressor and MYCN-repressed gene shown here to be re-
expressed following G9a inhibition is pro-apoptotic factor BOK (BCL-2-related ovarian 
killer). Whilst it is unknown through which mechanism BOK-driven apoptosis acts in 
this study, the data in this chapter suggests that the increase in BOK protein 
expression following G9a inhibition is the driver of apoptosis in MYCN-amplified 
neuroblastoma; there is no BOK induction in non-MYCN-amplified neuroblastoma 
following G9a inhibition and there is also no apoptosis either, whereas in MYCN-
amplified cells there were increases in both. Moreover, MYCN depletion also induced 
BOK gene and protein expression suggesting good prognostic indicator BOK to be a 
repressed MYCN target. Also, BOK depletion stopped apoptosis in MYCN-amplified 
Kelly cells following UNC0638 treatment. Therefore, this all suggests that BOK is a 
tumour suppressor and a novel inducer of apoptosis in MYCN-amplified 
neuroblastoma, and this is this potential mechanism for the synthetic lethality 
relationship between G9a-MYCN. 
It was initially reported that BOK-induced apoptosis was BAX/BAK-dependent. Mice 
deficient in both BAK and BAX are highly resistant to intrinsic apoptosis stimuli (340, 
341) even when endogenous BOK is expressed. This suggests it acts upstream of 
BAX and BAK in the intrinsic pathway (37). Yet, it has recently been demonstrated 
that BOK can efficiently induce cytochrome c release and apoptosis in the absence of 
BAK and BAX (323). Furthermore, it has been suggested BOK can influence the 
apoptotic response to chemotherapeutic drugs in ovarian carcinoma cells suggesting 
it is a genuine pro-apoptotic factor (323). Results from this chapter agree with this 
assessment as there is no increase in BAX or BAK protein following UNC0638 
inhibition despite the increase in BOK and apoptosis marker cPARP. 
Furthermore, the localisation of BOK is different to BAK and BAX as BOK localises 
mainly to the endoplasmic reticulum (ER) and the Golgi apparatus and only weakly to 
mitochondria (342). The ER stress pathway was targeted in mouse embryonic 
fibroblasts from BOK-/-  animals, with significantly less cell death in the BOK-/-  relative 
to wild type cells suggesting BOK promotes apoptosis following ER stress (36). BIX-
01294 treatment in bladder cancer cells has also been shown to stimulate ER stress 
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(305). Therefore mechanistically, this suggests that G9a inhibition increases ER stress 
in MYCN-amplified neuroblastoma and the decrease in MYCN allows for the re-
expression of BOK which localises to the ER to drive apoptosis and cell death via 
MOMP. Moreover, BOK can also be found in the nucleus and its export is regulated 
by the presence of nuclear export signal (NES) within its BH3 domain (37, 324, 343). 
This localisation event is suggested to play a big role in its apoptotic function as 
mutations in this export signal, and inhibition of NES-containing protein exporter Crm1 
increases the accumulation of BOK and thus its apoptotic potential (324). This 
suggests the importance of therapeutically regulating apoptosis through small 
molecule inhibitors.  
The result of differentiation following BOK depletion was very surprising and 
interesting as the role of the BOK in early development has not been well 
characterised. As apoptosis is a key process in the stages of development, it is 
necessary to dispose of unwanted cells and tissues during embryonal growth such as 
epithelial remodelling during gut development (344). Genetic manipulation in mice, 
drosophila, and nematodes has shown that the BCL-2 family has a pivotal role in 
contributing to development, not only by controlling cell death but also in many non-
apoptotic functions too (345). For example, BCL-2 proteins localised at the ER 
membrane can contribute to the control of Ca2+ exchanges at the level of the 
ER/mitochondria interface, or Ca2+ hotspots (346). Mitochondria uptake the Ca2+ 
released from the ER, however if mitochondria accumulate Ca2+ too quickly, this can 
lead to mitochondrial Ca2+ overload which can cause apoptosis or necrosis (347). This 
regulation of Ca2+ exchange is vital in the development of zebra fish and mice.  
In addition, it has recently been shown that anti-apoptotic proteins can act as 
transcriptional regulators outside of interacting with pro-apoptotic proteins at the outer 
mitochondrial membrane to promote cancer cell survival and growth. A pro-survival 
BCL-2 recognition sequence has been identified in the transcriptional regulator SUFU. 
MCL-1, BCL-2 and BCL-XL can then bind to tumour suppressor SUFU to inhibit its 
activity and loss of MCL-1, BCL-2 and BCL-XL results in accumulation of SUFU (348). 
Furthermore, when overexpressed in mesenchymal stem cells, these proteins can 
induce expression of BCL2 and MCL1 in a GLI1/GLI2 dependent manner suggesting 
that these pro-survival proteins can regulate themselves in a positive feedback loop 
(348). BOK binds strongly to inositol 1,4,5-trisphosphate receptors (IP3Rs), proteins 
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that form tetrameric calcium channels in the ER membrane to direct the release of 
calcium from the ER. It is suggested that BOK does not affect Ca2+ release, instead 
protecting the IP3Rs from proteolysis and controlling their expression, at least in 
mouse embryonic fibroblasts (349). This suggests that, like pro-survival proteins MCL-
1, BCL-2, and BCL-XL, pro-apoptotic protein BOK can also act as a transcriptional 
regulator, although the mechanism for this remains undefined. This may suggest how 



















6.1 Summary of findings 
In this study, the viability of enzyme histone methyltransferase G9a as a 
neuroblastoma therapeutic target has been assessed. It was determined that G9a is 
an oncogene in neuroblastoma with increased mRNA and protein in high-risk MYCN-
amplified correlating with poor prognosis. Depletion of G9a is able to inhibit 
proliferation in all tested cell lines, as well as inducing apoptotic cell death in MYCN-
amplified cell lines. 
The efficacy of small molecule inhibitors UNC0638 and UNC0642 was tested in a 
broad panel of MNA and non-MNA neuroblastoma cell lines with MNA cell lines being 
pointedly more sensitive to these inhibitors. Furthermore, the viability of disease-free 
cell lines RPE-1 and NF-TERT was unaffected at the highest concentration suggesting 
a synthetic lethal relationship between G9a and MYCN. 
G9a is shown to be a regulator of MYCN protein and novel repressed G9a targets 
have also been determined such as CCBE1, FABP3, and AMHR2. Pro-apoptotic and 
potential tumour suppressor BOK is shown here for the first time to be co-regulated by 
both G9a and MYCN. G9a depletion and inhibition in MNA cells increases BOK mRNA 
expression and BOK protein and this increase correlates with the increase in apoptotic 
cell death. Conversely, the depletion of BOK is shown here to help drive differentiation 
in Kelly and IMR32 cells suggesting there is more to BOK than just being a pro-
apoptotic factor.  
Furthermore, G9a depletion and inhibition was able to arrest cell proliferation in all 
neuroblastoma cells tested, irrespective of MYCN-amplification or overexpression 
therefore suggesting that G9a is a key oncoprotein in neuroblastoma. 
6.2 Depletion and inhibition of key oncoprotein G9a is synthetic lethal in MNA 
neuroblastoma 
Synthetic lethality between two genes is defined by the simultaneous loss of both 
genes is necessary for death to occur; single losses do not affect viability. When 
comparing the G9a and MYCN potential synthetic lethal relationship with the more 
established BRCA-PARP synthetic lethality, G9a and MYCN may not appear as 
straight forward a relationship as this at first glance.  
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In the BRCA example, mutations in tumour suppressors BRCA1 and BRCA2 lead to 
genetic instability and breast cancers arise (249). These mutations cause these types 
of breast cancer to be sensitive to PARP inhibitors as PARP plays a key role in the 
repair of DNA single-strand breaks. The accumulation of these breaks leads to DNA 
double-strand breaks at the replication forks which are ordinarily repaired by the error-
free homologous-recombination double-stranded DNA repair pathway of which key 
components are the tumour suppressors BRCA1 and 2 (350). Therefore, with BRCA1 
and 2 inhibited by the mutations and PARP inhibited therapeutically there is no method 
for the cell to repair this genomic instability which drives the cell to death. 
By comparison, in this thesis G9a depletion and inhibition by SMI UNC0638 is able to 
induce an apoptotic response selectively in MNA neuroblastoma. However, when 
depleted and inhibited in non-MNA lines, no apoptosis or cell death was induced 
(Chapter 3, 4). The apoptosis observed was further preferential to MYCN-amplification 
as engineered S21N cells that can express MYCN dependent on tetracycline 
exposure, displayed apoptosis only in the presence of MYCN (Chapter 3, 4). This 
shows how the inhibition of G9a causes apoptosis and cell death. 
Furthermore, the results from this study show G9a depletion and inhibition is able to 
decrease MYCN protein in all MNA cell lines tested. There was no effect on MYCN 
mRNA suggesting that the histone methyltransferase domain of G9a regulates MYCN 
stability by potentially methylating MYCN (Chapter 4, 5). Post-translational 
modifications of MYCN protein are required to regulate turnover of MYCN protein, as 
phosphorylation of serine 62 and threonine 58, and ubiquitination via FBXW7 direct 
the MYCN for proteosomal degradation (226, 227). Furthermore, arginine 
methyltransferase PRMT5 has also been shown to methylate MYCN to stabilise the 
protein (229), although the exact mechanistic reason for this methylation has yet to be 
elucidated. This reduction in MYCN was able to regulate MYCN targets as there is an 
increase in repressed targets CLU and CASP8, as well as a reduction in induction 
target ALK (Chapter 4). This all suggests that in the context of synthetic lethality, G9a 
inhibition leads to the depletion of MYCN protein which the MNA neuroblastoma cells 
can’t handle, thus driving them to cell death via apoptosis. 
However, it is suggested that the depletion of oncoprotein MYCN in Figure 5.2A leads 
to an increase in apoptosis indicator cPARP. This would suggest that the singular loss 
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of MYCN is enough to drive cell death and not the combined loss of G9a and MYCN 
suggesting oncogene addiction instead. However, it is also suggested in this thesis 
that in MNA cells there is a significant increase in the amount of G9a transcript and 
protein. Therefore, this suggests that the depletion of MYCN may lead to a decrease 
or inhibition of G9a protein which then would suggest a synthetic lethal relationship. 
This needs to be further examined to further establish the relationship between G9a 
and MYCN. 
6.3 G9a is a novel regulator of gene expression and apoptosis 
G9a is a known activator and repressor of gene expression, either directly through 
depositing repressive methylation marks on H3, or forming repressive complexes. 
Here novel repressed G9a targets are shown for the first time although it is not known 
how G9a represses these genes. It is presumed that these genes are potential tumour 
suppressor genes.  
The key novel repressed tumour suppressor gene shown here is BOK which is shown 
to be necessary for G9a-associated apoptosis to occur (Chapter 5). G9a depletion and 
inhibition was shown to increase BOK mRNA and BOK protein expression only in MNA 
neuroblastoma cells. This increase in expression was also exhibited in MYCN 
depleted cells leading to the hypothesis that MYCN may repress BOK, and the 
decrease in MYCN caused by G9a inhibition may drive BOK expression. BOK protein 
expression was shown to be inversely associated MYCN which supports this notion. 
LAN-1 saw the biggest increase in BOK mRNA when treated with UNC0638 for 24 
hours however when protein lysates were tested for BOK, there was no BOK 
observed. It is suggested that BOK promoter may be methylated however this increase 
in transcript would suggest there is more regulation in place.  
BOK expression was shown to correlate with apoptosis induced by G9a inhibition and 
depletion. When Kelly neuroblastoma cells depleted of BOK were treated with 
UNC0638, no cPARP  was observed and there was a significant decrease in cell death 
relative to the BOK wild type. This suggests that BOK is a true pro-apoptotic factor 
and potential tumour suppressor. 
Depletion of BOK also had an unforeseen side effect of helping IMR32 and Kelly 
neuroblastoma cells to differentiate. It was thought that if BOK acted as a true tumour 
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suppressor, then depletion of BOK would increase cell growth. However, it had the 
opposite effect where Kelly and IMR32 cells decreased in percentage phase 
confluence after BOK depletion. Furthermore, there was a consistent increase neurite 
length and neuritogenesis, along with a change in morphology in these cells after BOK 
depletion. These changes became consistently significant after 48 hours suggesting 
the changes are downstream of BOK depletion and not a direct effect. This seemingly 
only effected the MYCN-amplified cell lines tested as GIMEN and SKNAS cells were 
not affected, not shown. This would suggest that despite being repressed by MYCN 
to begin with, BOK plays a key role as a regulator whether that be through being 
induced or depleted. 
6.4 G9a and MYCN model 
Here is shown a graphical model of how G9a and MYCN block apoptotic cell death by 
repressing pro-apoptotic factor BOK. In wild type MYCN-amplified cell lines like Kelly 
(Figure 6A) it is suggested that G9a stabilises MYCN through an unknown mechanism. 
It is suggested that MYCN is a non-histone target for G9a and that G9a methylation 
helps to stabilise MYCN protein similar to that described by Park et al with PRMT5 
and MYCN (229). This is then able to represses G9a and MYCN targets. This includes 
BOK expression, again through an unknown mechanism, which then blocks apoptotic 
cell death.  
However, when G9a is either depleted via siRNA interference or inhibited via small 
molecule inhibitor UNC0638, MYCN is depleted as a result of potentially losing the 
methylation mark. This destabilisation allows for the re-expression of BOK which then 
leads to apoptotic cell death (Figure 6B). As this is a model explanation, there is still 




Figure 6 – Model of G9a and MYCN cooperation 
A – G9a may methylate MYCN protein to stabilise it. G9a and MYCN then cooperate to repress 
BOK expression. B – G9a inhibition and depletion destabilises MYCN to re-express BOK and 
drive apoptosis via MOMP, as detailed by Llambi et al (38). 
6.5 Future Studies 
In this study, a novel decrease in MYCN protein after G9a inhibition was shown. G9a 
has been shown to bind to c-MYC protein (339), which would suggest that it also binds 
to MYCN. As well-established post-translational phosphorylation and ubiquitination 
events of MYCN can regulate proteasomal degradation, it would be of interest to 
explore the interplay between MYCN and lysine methylation. For example, assessing 
if MYCN is methylated by G9a using liquid chromatography – tandem mass 
spectrometry (LC-MS/MS) analysis of immunoprecipitated MYCN protein similar to 
Park et al (229) and if this protects MYCN from degradation. In addition, the exact 
mechanism driving synthetic lethality between G9a and MYCN would need to be 





As current G9a inhibitors block the SET domain, they are not specific to just G9a as 
they also inhibit GLP. Therefore, understanding if depletion and inhibition of GLP has 
a similar effect on cell proliferation and apoptosis would be of interest. Furthermore, it 
would be of interest to determine if the genes shown to be re-expressed following G9a 
inhibition, would also become re-expressed following GLP inhibition.  
G9a is structurally and functionally similar to GLP and the results from this study 
suggest that wild type GLP is not able to rescue neuroblastoma cells from diminished 
proliferation and apoptotic cell death after G9a depletion and inhibition. Very little has 
been written about GLP and neuroblastoma with only one study depleting GLP in 
neuroblastoma to test the efficacy of their shRNA rather than any phenotypic effect 
(351). GLP has been suggested to aid the tumour suppressor activity of transcription 
factor regulator and metallothionein (MT) member MT1h which acts by enhancing the 
GLP methyltransferase activity on H3 (352). G9a and GLP both methylate H3 however 
it is suggested that G9a is more important than GLP for the in vivo histone 
methyltransferase function (120). Also, the ankyrin repeat domains of G9a and GLP 
have been shown to have differing binding affinities towards H3K9me1 and H3K9me2, 
with G9a preferring to associate with H3K9me2 and GLP associating with H3K9me1 
(122). This means the G9a-GLP heterodimer can bind to both H3K9me1 and 
H3K9me2 marks to recruit G9a-GLP complexes. Therefore, depleting of either G9a or 
GLP may hinder cell proliferation or drive apoptosis if it is mechanistically driven via 
these complexes. This suggests that GLP could also play a role as an oncoprotein 
and this needs to be evaluated to help clarify the mechanistic role of G9a too. 
Finally, here novel G9a targets have also been determined such as pro-apoptotic and 
potential tumour suppressor BOK which is shown for the first time to be co-regulated 
by both G9a and MYCN. This is potentially through G9a and MYCN protein interaction 
to form a repressive complex which either binds directly to the BOK promoter to block 
a potential transcription factor, or blocks expression of said transcription factor. 
Therefore, determining the mechanistic cause for how G9a and MYCN repress BOK 
protein would be useful for determining how to increase the expression of good 
prognostic indicator BOK in other cancer cell lines, and if this can be combined with 
therapeutic treatments. Also determining the role BOK plays in differentiation needs 
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